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ABSTRACT 
      Ruminant Campylobacter, (C. jejuni and C. coli), contributes significantly to 
foodborne illnesses in humans. A recently emerged C. jejuni clone (named SA) is also a 
major cause of ruminant abortion in the United States. Despite the importance of 
Campylobacter in ruminant health and food safety, little is known about its prevalence 
and antibiotic resistance profiles in cattle production systems in the U.S. In this project, 
we examined the antibiotic resistance and mechanisms of the Campylobacter isolates 
derived from 35 feedlot cattle farms in 5 different states, and determined the distribution 
of C. jejuni clone SA in the feedlots and in dairy cows by using isolates collected by 
NAHMS Dairy Studies 2002, 2007 and 2014. In feedlot cattle, clone SA accounted for 
5.8% of the total C. jejuni isolates, but prevalence varied from farm to farm. In dairy 
cattle, the overall prevalence of clone SA was 7.2%, and a declining trend in the 
cprevalence was detected from 2002 to 2014.  Whole genome sequence analyses of the 
dairy isolates revealed the high genomic stability of clone SA over the years. The results 
also revealed high prevalence of fluoroquinolone (FQ) resistance in the feedlot cattle 
isolates. Molecular typing revealed that clonal expansion was involved in dissemination 
of FQ-resistant C. coli. Notably, florfenicol resistance, which was historically low in 
Campylobacter, also emerged in the bovine Campylobacter isolates. Whole genome 
sequencing analysis identified a novel cfr variant, named cfr(C), in the florfenicol-
resistant isolates. Cloning of cfr (C) and conjugative transfer of the cfr (C)-containing 
plasmid confirmed its role in conferring resistance to multiple classes of antibiotics 
including phenicols, lincosamides, pleuromutilins, and oxazolidinones. The cfr(C) gene 
was detected in 10% of the C. coli isolates, and molecular typing revealed its spread 
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mainly via clonal expansion. These findings reveal the common presence of C. jejuni 
clone SA in both beef and dairy cattle and the rising prevalence of FQ-resistant 
Campylobacter as well as the emergence of a novel multidrug resistant mechanism 
Cfr(C) in ruminant Campylobacter in the U.S.  These results provide new insights into 
the epidemiology and antibiotic resistance of Campylobacter in the bovine reservoirs. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Campylobacter is one of the most important foodborne pathogens that cause 
bacterial gastroenteritis worldwide.1 It is also a major cause of abortion in ruminants, 
especially in sheep, resulting in significant economic loss to producers. Recently, a 
tetracycline-resistant C. jejuni strain (named clone SA) has become the predominant 
cause of sheep abortion in the U.S.2 Clone SA has been also associated a number of 
foodborne illnesses due to consumption of raw milk.3 Despite the importance of C. jejuni 
clone SA in food safety and ruminant health, little is known about its distribution and 
epidemiology in the U.S. cattle production systems. 
Campylobacter is becoming increasingly resistant to various antibiotics. Due to 
the consequence of antibiotic resistance for treating human campylobacteriosis, 
antibiotic-resistant Campylobacter is considered a serious antibiotic resistance threat in 
the U.S. and worldwide（https://www.cdc.gov/drugresistance/threat-report-2013/）.4  As 
a foodborne pathogen widely distributed in food producing animals, Campylobacter is 
exposed to antimicrobials used for food animal production. Antibiotics such as 
fluoroquinolone (FQ) and florfenicol are frequently used in cattle for disease prevention 
and control in the U.S., but little is known about antibiotic resistance in bovine 
Campylobacter.  
The purposes of this project were to determine the molecular epidemiology of C. 
jejuni clone SA in beef and dairy cattle and examine antibiotic resistance profiles of 
Campylobacter isolates from cattle. To achieve the goals, we conducted a prospective 
study on 35 feedlot cattle farms in multiple states in the U.S. and collected 2,292 
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Campylobacter isolates. In collaboration, we also analyzed Campylobacter isolates 
derived from the NAHMS (National Animal Health Monitoring System) Dairy Studies 
2002, 2007 and 2014.5, 6 In the first part of the research, we focused on determing the 
prevalence and molecular epidemiology of C. jejuni clone SA. In feedlot cattle, the 
overall prevalence of Campylobacter was 72.2%, of which 82.1% were C. jejuni. Clone 
SA accounted for 5.8% of the total C. jejuni isolates, but its prevalence varied with 
feedlots and states.  Interestingly, starlings on the feedlots harbored C. jejuni including 
clone SA, suggesting it plays a role in the transmission of Campylobacter. However, 
starling intervention on the farms did not affect the prevalence of Campylobacter 
including clone SA. In dairy cattle, the overall prevalence of clone SA was 7.2%, but a 
declining trend in the prevalence was detected from 2002 to 2014. Whole genomic 
sequence analysis of the dairy clone SA isolates revealed that they are genetically stable 
over the years and most of the isolates carried the tetracycline resistance tet(O) gene in 
the chromosome. These findings indicate clone SA is widely distributed in both beef and 
dairy cattle and provide new insights into the molecular epidemiology of clone SA in 
ruminants. In the second part of the research, we analyzed the antimicrobial 
susceptibilities of 320 C. jejuni and 115 C. coli isolates obtained from the feedlot cattle 
farms. The results indicate that fluoroquinolone resistance reached to 35.4% in C. jejuni 
and 74.4% in C. coli, which are significantly higher than those previously reported in the 
U.S. While all fluoroquinolone resistant (FQR) C. coli isolates examined in this study 
harbored the single Thr-86-Ile mutation in GyrA, FQR C. jejuni isolates had other 
mutations in GyrA in addition to the Thr-86-Ile change. Notably, most of the analyzed 
FQR C. coli isolates had similar PFGE patterns and the same MLST sequence type (ST-
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1068), regardless of their geographic sources and time of isolation, while the analyzed C. 
jejuni isolates were genetically diverse, suggesting that clonal expansion is involved in 
dissemination of FQR C. coli but not C. jejuni. These findings reveal the rising prevalence 
of FQR Campylobacter in the U.S. and provide novel information on the epidemiology of 
antibiotic-resistant Campylobacter in the ruminant reservoir. In the third part of the 
research, a novel multidrug resistance mechanism, named cfr(C), was identified in 
florfenicol-resistant C. coli isolates of cattle origin. Cfr(C) is a a new variant of Cfr, and 
is divergent from Cfr (55.1% amino acid identity) and Cfr(B) (54.9% amino acid 
identity). The cfr(C) gene was located on a conjugative plasmid of ~48 kb.  Cloning of 
cfr(C) into C. jejuni NCTC11168 and conjugative transfer of the cfr(C)-containing 
plasmid confirmed its role in conferring resistance to phenicols, lincosamides, 
pleuromutilins, and oxazolidinones, and resulted in 8- to 256-fold increase in their MICs 
in both C. jejuni and C. coli. The cfr(C) gene was detected in 10% of C. coli isolates 
derived from different cattle farms in different states, and molecular typing of the cfr(C)-
positive C. coli isolates revealed its spread mainly via clonal expansion. These results 
identify cfr(C) as a new multidrug resistance mechanism in Campylobacter and suggest 
the potential transmission of this mechanism via the foodborne route. Altogether, 
findings in this dissertation provide new and critically needed information about 
pathogenic and antibiotic-resistant Campylobacter in the cattle reservoirs in the U.S., 
which will faciliate the control of this major zoonotic pathogen and its transmission 
through the food chain.  
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Dissertation Organization 
     This dissertation is organized into six chapters, including a general introduction, a 
literature review, three chapters on research for publication, and a final summary. 
Chapter 1 is a general introduction for the Ph.D. project. Chapter 2 is a literature review 
of Campylobacter and antibiotic resistance in Cattle. Chapter 3 is a manuscript prepared 
to be submitted to Applied and Environmental Microbiology. Chapter 4 has been 
accepted for publication in Scientific Reports. Chapter 5 has been published in the 
Journal of Antimicrobial Chemotherapy. Chapter 6 is the overall summary of this project 
which includes the general conclusions. The references of this dissertation are located at 
the ends of chapters 2, 3, 4, and 5, and are formatted according to the style of the Journal 
of Antimicrobial Chemotherapy except for those that are to be submitted or have been 
published in different journals. All the tables, figures, and legends in chapter 3, 4, and 5 
are placed as close as possible to the original text references. 
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CHAPTER 2: LITERATURE REVIEW 
Antibiotic resistance in foodborne pathogen Campylobacter 
1. Introduction 
     Campylobacter species, particularly Campylobacter jejuni and Campylobacter coli, 
are a major cause of foodborne bacterial gastroenteritis in humans.1 According to the 
Centers for Disease Control and Prevention (CDC), Campylobacter is responsible for 1.3 
million cases of foodborne illness annually in the U.S. It was also estimated that 
Campylobacter sp. are responsible for 400-500 million cases of diarrhea each year 
worldwide.1 Transmission of Campylobacter to humans occurs mainly through 
consumption of contaminated food of animal origin, particularly raw or undercooked 
poultry meat, unpasteurized milk, and dairy products.2-4  Although the majority of 
Campylobacter infections are self-limiting and do not require antimicrobial treatment and 
usually resolve within a few days without antibiotic treatment, severe or prolonged 
infection can occur, particularly in young, elderly, and individuals with compromised 
immunity.4 In these circumstances, fluoroquinolone (FQ) and macrolides are considered 
as the drugs of choice for the treatment, and tetracycline is an alternative drug but should 
be avoided in young children and pregnant women.4, 5 Intravenous administration of 
aminoglycosides are only used for the treatment of serious bacteremia and other systemic 
infection due to Campylobacter. 6 However, Campylobacter is increasingly resistant to 
clinically important antibiotics and the CDC has recently identified drug-resistant 
Campylobacter as a serious antibiotic resistance threat in the United States.7 Thus, 
enhanced efforts are needed to curb the prevalence and transmission of antibiotic-
resistant Campylobacter.  
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     As a foodborne pathogen, Campylobacter is commonly present in food producing 
animals. Poultry, especially market-age broiler chickens, are frequently colonized by C. 
jejuni in the intestinal tract, and consequently chicken carcasses are often contaminated 
by Campylobacter during the slaughtering process.8 Thus, consumption of undercooked 
poultry meat is a major risk factor for Campylobacter infections.9 In addition to poultry, 
cattle also contribute significantly to outbreaks and sporadic cases of campylobacteriosis 
in humans.10, 11 Cattle Campylobacter can reach humans via multiple transmission routes 
including direct contact (e.g. petting zoo and occupational exposure), consumption of 
unpasteurized milk (and associated dairy products), and environmental contamination 
(water, produce, etc.).2, 3, 12 Molecular typing of C. jejuni isolates from various sources 
using multilocus sequence typing (MLST) attributed approximately 40% of sporadic 
human cases to cattle sources in the United Kingdom.13 The contribution of cattle 
Campylobacter to outbreaks of human campylobacteriosis is even more prominent 
because Campylobacter from cattle feces frequently contaminates raw milk.2, 14-16 
Ruminant Campylobacter may also contaminate water supplies via agricultural runoff, 
leading to large waterborne outbreaks.12 Of note, red meat is infrequently contaminated 
by Campylobacter17 and does not appear to play a major role in the transmission of 
Campylobacter to humans. Additionally, ruminants are an integral part of Campylobacter 
ecology and may serve as a source of Campylobacter transmission to the environment 
and other farm animals, such as poultry.  Thus, cattle are one of the most important 
animal reservoirs for this zoonotic pathogen. 
     For the past decades, many studies have been performed to understand the 
epidemiology and mechanisms of antibiotic resistance in Campylobacter. This chapter 
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will summarize the current knowledge of antibiotic resistance in Campylobacter with a 
focus on clinically important and newly discovered antibiotic resistance. The recent 
emergence of a tetracycline-resistant C. jejuni clone associated with ruminant abortion 
will also be discussed. 
2.  Antimicrobial susceptibility tests for Campylobacter 
     Although Campylobacter has been long recognized as an important pathogen and 
many methods have been used for testing Campylobacter susceptibility to various 
antibiotics, a standardized test was not available until 2004. 18  Currently, three testing 
methods for Campylobacter have been standardized by Clinical and Laboratory Standard 
Institutes (CLSI) in the U.S. and by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) in European. These methods include disk diffusion, 
agar dilution, and broth microdilution. A previous study compared the agar dilution and 
the agar disk diffusion methods and found agar diffusion can be used as a reliable 
alternative method for susceptibility testing of thermophilic Campylobacter to several 
classes of antimicrobial agents, particularly to quinolone/fluoroquinolones and 
aminoglycosides.19 However, in the U.S., agar dilution and broth microdilution are 
currently the methods of choice for Campylobacter susceptibility testing. To perform 
such dilution tests, a series of plates or tubes (or wells in a microtiter plate) containing 
two-fold serial dilutions of the antimicrobial agent are prepared, to which are added a 
standardized suspension of the organism to be tested, plus a control plate or tube that 
doesn’t receive any antibiotics. After incubation at 42 ℃ for 24h under microaerobic 
conditions (5% O2, 10% CO2, and 85% N2), the MICs are determined as the lowest 
antimicrobial concentration that inhibits bacterial growth. Agar dilution was the first 
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standardized susceptibility testing method for thermophilic Campylobacter species.18 
Although it is reliable and highly reproducible and also provides quantitative MICs, it is a 
labor-intensive, time-consuming and costly test.19 On the other hand, the broth dilution 
method is simple, inexpensive, and standardization can be achieved by using C. 
jejuni and C. coli type strains as controls. Therefore, the broth microdilution method has 
been commonly used for determination of the antibiotic susceptibility patterns of 
Campylobacter spp.20 
3. Prevalence and trends of antibiotic resistance in Campylobacter 
     Increase in the incidence of Campylobacter strains resistant to antimicrobial agents, 
particularly to FQs, has been reported in many countries worldwide.21-24 FQ-resistant C. 
jejuni was detected during the late 1980s in Europe, where researchers suggested that 
such resistance was due, in part, to use of FQ antibiotics in animal production.5  Several 
studies linked the clinical usage of FQs with the emergence and spread of FQ-resistant 
Campylobacter.25-27 In the United States, the introduction of sarafloxacin and 
enrofloxacin in the mid-1990s for use in poultry flocks for disease control contributed to 
the rise FQ resistance.28 Although use of FQs in poultry was not intended for control of 
Campylobacter, the antibiotic selection promotes rapid emergence of FQ-resistant 
Campylobacter,29, 30 which is commonly present in the intestinal tract of poultry.  Before 
1992, FQ-resistant C. jejuni was rarely observed in U.S., whereas from 1992 to 2001, 
FQ-resistant C. jejuni of human origin increased from 1.3% to 40.5%.28 A similar trend in 
FQ resistance among Campylobacter isolates was also reported in other countries. For 
example, ciprofloxacin resistance among Campylobacter species from humans increased 
from zero before 1991 to 84% in 1995 in Thailand.31 A study across 17 years showed that 
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the rates of ciprofloxacin resistance of clinical C. jejuni isolated in China increased from 
50% to 93.1% between 1994 and 2010.32 A recent study from China even found that 
almost 100% of the C. jejuni and C. coli isolates from chicken and swine were resistant to 
FQs.33 In Spain, FQ resistance among clinical Campylobacter isolates was not observed 
in 1987, however in 1991 the frequency of FQ-resistant Campylobacter strains has 
increased remarkably to 30%.25 Additionally, a steady increase in FQ-resistance among 
Campylobacter isolates has also been observed in many European countries.22, 34-36  
     Compared to FQ resistance, macrolide resistance is much less prevalent in 
Campylobacter. However, increased prevalence of macrolide resistance among C. jejuni 
and C. coli has been reported in both developed and developing countries, but the 
situation seems to be more severe in C. coli and in developing countries.33  The 
prevalence of macrolide resistant Campylobacter also vary greatly in different countries 
and sources. In most of the developed countries, the macrolide resistant rate is less than 
10%, which is still within the range of control.5, 37 In the U.S., studies conducted by the 
National Animal Health Monitoring System (NAHMS) Dairy 2002 and Dairy 2007 
reported that 0.4% of Campylobacter isolates were resistant to erythromycin.38 In the 
2014 NARMS (National Antimicrobial Resistance Monitoring System) integrated report, 
erythromycin resistance in C. jejuni isolates from both human and chicken sources 
remained low (< 2%). Similar findings also were observed in European countries, where 
macrolide resistance among Campylobacter isolates from human and C. jejuni isolates 
from chicken and cattle has been low and stable.39-41 However, in the case of 
Campylobacter isolates of animal origin from some developing countries, high 
prevalence of macrolide resistance in Campylobacter isolates, especially in C. coli from 
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poultry and swine, has been reported in several studies.33, 42-44  This may be related to the 
use of macrolide agents as feed additives or for treating infections. Interestingly, many 
studies have found that macrolide-resistant C. coli is much more prevalent than 
macrolide-resistant C. jejuni.33, 42, 43 For example, a recent report from China indicated 
that less than 10% of C. jejuni isolated from human, chicken and swine were resistant to 
macrolides, while up to 73.2% of C. coli isolates were resistant to the antibiotics. 33 The 
exact reason for the much higher prevalence of macrolide resistance in C. coli is 
unknown, but it might suggest that C. coli is intrinsically more capable of acquiring 
macrolide resistance.  
     The prevalence of chloramphenicol and florfenicol resistance in Campylobacter has 
been low, but is highly variable depending on the geographic areas and the host species. 
In China, Zhou et. al. analyzed 203 Campylobacter isolates from stool samples of 
diarrhea patients collected between 1994 and 2010 and found the overall rate of 
florfenicol resistance was 31.5%, lowest at 12% in 1997-1999 and highest at 62% in 2009 
-2010.32 Ma et. al isolated 259 Campylobacter isolates along a broiler chicken production 
chain and found the prevalence of florfenicol resistance in C. jejuni (37.7%) was 
significantly higher than that in C. coli (7.8%).45 In another study analyzing antibiotic 
resistance from broiler chickens, the florfenicol resistance rate of C. jejuni (79.8%) was 
found to be much higher than that of C. coli (6.4%).46 In the U.S., no chloramphenicol or 
florfenicol resistance in C. jejuni isolates was detected in NAHMS Dairy 2002 and 2007 
studies.38  Similarly, NARMS analyzed 2,258 Campylobacter jejuni, 925 Campylobacter 
coli, and 7 Campylobacter lari isolates from retail meat and collected between 2002 and 
2007 and found no resistance to florfenicol.47 The differences in florfenicol resistance 
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rates in different countries are likely due to differences in the practice using this class of 
antibiotics for animal agriculture.  
4. Mechanisms of antibiotic resistance in Campylobacter  
     Campylobacter has developed multiple mechanisms to counteract the selection 
pressure from antimicrobial agents. These mechanisms include (i) restricting the access 
of antibiotics to their targets, which includes reducing the membrane permeability and 
increasing extrusion of antibiotics by efflux pumps, (ii) modification or protection of 
antibiotic targets, (iii) modification or inactivation of antibiotics. Some or all of these 
mechanism may act together in the resistance to a single antibiotic. In the following 
sections, mechanisms involved in Campylobacter resistance to fluoroquinolone, 
macrolides and florfenicol will be discussed due to their clinical significance or 
importance for animal production. 
4.1. Fluoroquinolone resistance  
     The quinolones are a class of broad spectrum antimicrobials that are potent against 
both gram-negative and gram-positive bacteria.48 According to their spectrum of activity, 
quinolones have been classified into four generations. The majority of quinolones 
currently used for clinical therapies are FQs, which are derived from the quinolones by a 
fluorine substitution at 6-position or C-7 position, thereby increasing their activity against 
gram-negative bacteria.48 Once inside the bacterial cells, FQ antimicrobials exert their 
antibacterial effect by interacting with DNA gyrase and topoisomerase IV, resulting in 
double-stand DNA breaks and cell death.49 Two main mechanisms of resistance to 
fluoroquinolones are currently recognized in Campylobacter bacteria, including 
mutations that change the antibiotics target and reduce antibiotic intracellular 
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accumulation. In other gram-negative bacteria, target protection mediated by the Qnr 
protein was also involved in FQ resistance,50 but this mechanism has not been reported in 
Campylobacter. 
     Target mutations. In gram-negative bacteria, gyrase is the main target of 
fluoroquinolone antibiotics, whereas, in gram-positive bacteria, topoisomerase IV is more 
susceptible to the action of fluoroquinolone.49 Both enzymes consisting of two pairs of 
subunits, named GyrA and GyrB (DNA gyrase), and ParC and ParE (topoisomerase 
IV).51 Although most bacteria have both enzymes, Campylobacter lacks the parC and 
parE genes and thus parC/parE mutations are not involved in Campylobacter resistance 
to FQ antimicrobials.52-54 Additionally, no mutations in gyrB have been associated with 
FQ resistance in Campylobacter.52 Therefore, mutations linked to FQ resistance in C. 
jejuni and C. coli mainly occur in GyrA. Specifically, resistance to FQs involves amino 
acid substitutions in a region of the GyrA termed the “quinolone-resistance–determining 
region” (QRDR). This region is located within the DNA-binding domain on the surface 
of DNA gyrase and corresponding amino acids spans from position 51 to position 106 (E. 
coli numbering), with common mutations at amino acid positions 83 and 87 (position 86 
and 90 in Campylobacter).55 The most frequent mutation observed in FQ-resistant  
Campylobacter isolates is Thr-86-Ile, followed by Asp-90-Asn, Thr-86-Lys, Thr-86-Ala, 
Thr-86-Val, Asp-90-Tyr and Ala-70-Thr.5, 56, 57 The Thr-86-Ile mutation confers a high 
level of FQ resistance (ciprofloxacin MIC ≥ 16 µl/ml) in Campylobacter, while other 
mutations are associated with a low to medium level of resistance (MIC = 1-8 µg/ml).51, 
56, 58  Double mutations including Thr-86-Ile/Pro-104-Ser and Thr-86-Ile/Asp-90-Asn 
have also been linked to FQ resistance in Campylobacter.51 Additionally, acquisition of 
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high-level FQ resistance in Campylobacter does not require stepwise accumulation of 
point mutations in gyrA. Instead, a single point mutation in gyrA can lead to clinically 
relevant levels of resistance to FQ antimicrobials.56-60 
     Efflux. The CmeABC efflux pump contributes significantly to both intrinsic and 
acquired resistance of C. jejuni to FQ antimicrobials by reducing the accumulation of 
FQs in Campylobacter cells.61 In wild type 81-176, inactivation of CmeB led to a 8-fold 
reduction in the MIC of ciprofloxacin (from 0.313 to 0.039 ug/mL), suggesting that 
CmeABC contributes to the intrinsic resistance of Campylobacter to FQs.62 Luo et al 
found that insertional mutagenesis of CmeABC led to at least 21-fold reduction in 
ciprofloxacin MICs of various FQR isolates harboring resistance-conferring GyrA 
mutations.56  By contrast, overexpression of CmeABC, either by inactivating its repressor 
CmeR or mutating the promoter region of cmeABC, can increase the resistance to FQs in 
Campylobacter.63, 64. Additionally, CmeABC facilitates and promotes the emergence of 
FQR Campylobacter under selection pressure because GyrA mutations are not sufficient 
to survive the killing effect of ciprofloxacin.58 In the absence of a functional CmeABC, 
many spontaneous gyrA mutants would not be able to emerge under antibiotic selection.58 
Recently, a resistance-enhancing CmeABC variant has been identified in C. jejuni, which 
confers an exceedingly high-level resistance (ciprofloxacin MIC≥ 256 µg/ml) to FQs in 
the presence of GyrA mutations.64 
4.2. Macrolide resistance  
     Macrolide antibiotics, such as erythromycin, azithromycin, clarithromycin, and 
relithromycin, are a class of natural products that consist of a large macrocyclic lactone 
ring, which are usually 14-, 15-, or 16-membered.65 Macrolides inhibit protein synthesis 
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by binding to the ribosome that includes 23S rRNA and ribosomal proteins. Macrolides 
are usually used for the treatment of gram-positive cocci (mainly staphylococci and 
streptococci), gram-positive bacilli, gram-negative cocci, as well as some gram-negative 
bacilli, such as Campylobacter and helicobacter.66 In the case of Campylobacter 
infection, macrolides such as erythromycin are often considered the drug of choice for the 
clinical treatment. Three mechanisms involved in macrolide resistance in bacteria include 
i) modification of target site by point mutation or methylation, ii) active efflux antibiotics 
from bacteria cell, and iii) antibiotics inactivation. In Campylobacter, the first two 
mechanisms have been documented, but macrolide inactivation by the action of esterases 
and/or phosphotransferases has not been reported.  
     Modification of target site. A common mechanism for target modification is 
mutation, which occurs as base substitutions at positions 2074 and 2075 of the 23S 
rRNA, corresponding to positions 2058 and 2059 in E. coli, respectively. These two 
nucleotides interact directly with macrolide and the resulting protein changes impair the 
binding of the macrolides to its target.65  To date, four kinds of point mutations at 23S 
rRNA have been associated with macrolide resistance in Campylobacter species, 
including A2074C, A2074G, A2074T and A2075G. Among these point mutations, 
A2075G was observed most frequently.67-69 C. jejuni and C. coli have three copies of 23S 
rRNA (rrn operon). In most clinical strains that are highly resistant to erythromycin 
(MIC > 128 ug/mL), all three copies of rrn operons were mutated.69-71 When the A2074T 
mutation occured only in some of the rrn operons, it only conferred a low level resistance 
to macrolide.68 However, when the A2074T mutations happened in all 3 copies of 23S 
rRNA genes, the mutant strains were highly resistant to macrolide.72  
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     Modification of the ribosomal protein L4 and L22 has also been found conferring 
macrolide resistance in Campylobacter.  L4 and L22 were encoded by the rplD and rplV 
genes, respectively, and both were considered as a portion of the peptide exit tunnel of 
50S ribosome. Amino acids spanning positions 63–74 are reported to be the most 
important target regions of the L4 protein.73 Mutation in this region had been reported in 
several bacteria with high level of erythromycin resistance. 74-76 In Campylobacter, the 
G74D modification alone was found to confer low to medium resistance to macrolides.77 
Outside the 63-74 amino acid region of L4, several other amino acid substitutions were 
associated with macrolide resistance in both Campylobacter and Streptococcus.73, 78 The 
L22 modifications, including insertion, mutation, and deletion are also involved in 
macrolide resistance in Campylobacter. Corcoran et.al identified a unique A103V 
substitution in the L22 protein, which was linked to high level erythromycin resistance in 
both C. jejuni and C. coli.73 Three to four amino acid insertion at position 86 or 98 of the 
L22 protein were also observed in macrolide resistant isolates.79, 80  
     Recently, a new mechanism of macrolide resistance in Campylobacter has emerged,81 
which is mediated by the erm(B) gene that encodes a rRNA methyltransferase. This 
enzyme adds methyl groups to the A2058 (E. coli numbering) position located within a 
conserved region of domain V of the 23S rRNA. The consequence of methylation at the 
overlapping binding site gives rise to cross-resistance to macrolides, lincosamides, and 
streptogramins B (MLSB phenotype). To date, 43 erm (erythromycin ribosome 
methylase) genes have been reported (http://faculty.washington.edu/marilynr/), but only 
erm(B) has been detected in Campylobacter including C. jejuni and C. coli  in China and  
Europe.81-83 In the first report of erm(B) in C. coli, it was identified in a 12,035 bp 
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genomic segment on the chromosome and was found to confer a high-level resistance to 
erythromycin (MIC 512 µg/mL) . This segment contained 17 open reading frames 
(ORFs), 8 of which were antibiotic resistance determinants including erm(B),  tet(O) and 
6 genes encoding aminoglycoside-modifying enzymes.81 Thus the genomic segment was 
named as multidrug-resistant genomic island (MDRGI). This MDRGI can be transferred 
between C. jejuni and C. coli via natural transformation.81 The erm(B) gene was also later 
identified in C. jejuni, where it was associated with several antimicrobial resistance genes 
[ tet(O), aadE and aad9] in an MDRGI that was inserted in the chromosome at a different 
location when compared with that in C. coli.83 In Europe, the identified erm(B) in C. coli 
was also located in a MDRGI, but the MDRGI contents were different from those found 
in China.82 Interestingly, the erm(B)-carrying MDRGIs have different G + C contents 
from the rest of the chromosome, which suggests that Campylobacter acquired erm(B) 
from other bacterial organisms via horizontal gene transfer.82 
     Efflux of macrolides. The multidrug efflux pump CmeABC contributes significantly 
to macrolide resistance in Campylobacter. The contribution of CmeABC to erythromycin 
resistance was first demonstrated by an insertional mutation of the cmeB gene in wild-
type 81-176, which resulted in a 4-fold decrease in the MIC of erythromycin.62 While in 
the highly resistant strains (harboring the A2075G mutation in the 23S rRNA), the MICs 
of erythromycin decreased 128- to 256- fold after inactivating the cmeB gene.84 In 
contrast, overexpression of CmeABC by mutating the CmeR repressor led to 4-fold 
increase in the resistance to erythromycin.63  A number of studies demonstrated the role 
of antibiotic efflux in conferring both intrinsic and acquired resistance to macrolides by 
using the efflux pump inhibitor (EPI), phenylalanine-arginine β-naphthylamide 
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(PAβN).73, 85-87 PAβN was first identified as an inhibitor of the Pseudomonas aeruginosa 
efflux pump, and has been shown to be active in other gram-negative bacteria, including 
Campylobacter.87, 88 Regarding the effect of EPI on macrolide resistance, two 
mechanisms are present in C. jejuni and C. coli depending upon the level of resistance.  
In isolates with low level of erythromycin resistance (MICs 8–16 ug/mL) and no 
mutations in the 23S rRNA, the EPI can restore the susceptibility to erythromycin and 
clarithromycin to the wild-type level.85 In isolates with high-level erythromycin 
resistance (MIC > 128mg/L), the resistance is associated with a mutation in the 23S 
rRNA gene. In these isolates, the EPI leads to 2- to 4-fold decrease in erythromycin 
resistance.85, 86 These results suggest that antibiotic efflux may play a role not only in 
intrinsic resistance but also in acquired low-level resistance to erythromycin in 
Campylobacter. 
4.3. Florfenicol resistance  
     Florfenicol is a fluorinated derivative of thiamphenicol and is only used in veterinary 
medicine since its introduction in the mid-1990s.89  Florfenicol has a broad antibacterial 
spectrum against both gram-positive and gram-negative organisms, and shows a good 
tissue penetration due to its lipophilicity.90 Once in a bacterial cell, florfenicol binds to 
the peptidyltransferase centre to prevent the peptide chain elongation, resulting in 
inhibition of protein synthesis and bacterial death. Over the years, bacteria have 
developed several mechanisms to counteract the selection pressure from florfenicol, 
including (i) modification or protection of the antibiotic targets and (ii) decrease of 
intracellular concentration by reducing the permeability and increasing efflux. 
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     Modification or protection of the antibiotic targets. Functioning as an rRNA 
methyltransferase, Cfr plays an important role in bacterial resistance to florfenicol. 
Functional characterization found that Cfr adds a methyl group at position A2503 of 23S 
rRNA.91  Given that position A2503 of 23S rRNA is located at the peptidyl transferase 
centre, which is the target of a number of antimicrobial agents, modification of this 
position affects binding of multiple classes of antibiotics. Indeed, antimicrobial 
susceptibility testing revealed that S. aureus and E. coli strains expressing the cfr gene 
showed resistance to five chemically distinct classes of antimicrobials, including  
phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A (known as 
the PhLOPSA phenotype).92 The cfr gene was first discovered on a 16.5-kbp plasmid 
from Staphylococcus sciuri isolate of bovine origin in 2000.93 Since its first discovery, cfr 
has been detected in a number of Gram-positive and Gram-negative bacteria.93-97 The cfr 
gene is often carried by transferable plasmids with additional antibiotic resistance genes, 
which further facilitates its dissemination and emergence in different bacterial species 
and genera.98-101 A cfr-like gene, cfr(B), was discovered in a mobile genetic element in 
both Peptoclostridium difficile and Enterococcus faecium of human origin.102, 103 Cfr(B) 
shares 74.9% identity in amino acid (aa) sequences with the original Cfr and confers the 
same multidrug resistance phenotype.102 
      Recently, a novel cfr-like gene, named cfr(C), was identified in C. coli of feedlot 
cattle origin. cfr(C) was located on a conjugative plasmid of ~48 kb104 and encodes a  379 
aa protein that only shows 55.1% or 54.9% identity to the original Cfr from 
Staphylococcus sciuri93 or the recently reported Cfr(B) from E. faecium (Fig. 3).102  
Cloning of cfr(C) into C. jejuni NCTC11168 and conjugative transfer of the cfr(C)-
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containing plasmid confirmed its role in conferring resistance to phenicols, lincosamides, 
pleuromutilins, and oxazolidinones, which resulted in 8- to 256-fold increase in their 
MICs in both C. jejuni and C. coli. These findings established Cfr(C) as a novel 
multidrug resistance gene and represent the first report of a cfr-like gene in a foodborne 
pathogen.  
     In addition to Cfr, mutation in the antibiotic target also confers resistance to 
florfenicol. Recently, a G2073A mutation in all three copies of 23S rRNA was shown to 
mediate resistance to chloramphenicol and florfenicol in C. jejuni.105 
     Decreasing intracellular concentration of antibiotics. The CmeABC in C. jejuni 
NCTC 11168 had limited effect on florfenicol resistance.104 However, the “super” efflux 
pump variant, RE-CmeABC, is much more potent in conferring resistance to florfenicol 
and other antibiotics.64 The CmeB of RE-CmeABC shares only ~81% identity with the 
CmeB of NCTC 11168, and variations in the drug-binding pocket likely affect its 
function. Acquisition of RE-CmeABC alone resulted in 8-fold increase in the MIC of 
florfenicol.64 Drug accumulation assay confirmed the efflux function of Re-CmeABC.64  
      The floR gene, encoding a multidrug resistance efflux pump, mediates resistance to 
chloramphenicol and florfenicol.106 It was first discovered in Salmonella typhimurium 
DT104106 and had also been found in Campylobacter coli.107 floR encodes a protein of 
404 amino acids, which functions as efflux transporter. Interestingly, a number of genes, 
including pp-flo, florSt, flo, and floR, are closely related even though they were assigned 
to different designations in the literatures.106, 108, 109 Functionally, they all confer 
resistance to both chloramphenicol and florfenicol. Sequence alignment showed 96 – 
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100% identity in nucleotide sequences and 88% - 110% identity in the amino acid 
sequences. The fexA and fexB genes, coding for phenicol specific efflux pumps, also  
confer resistance to florfenicol. They have been found in staphylococci, bacillus, and 
enterococcus, but not in Campylobacter. 95, 110, 111 
 5. Tetracycline resistance and emergence of a highly pathogenic C. jejuni clone 
     Tetracyclines are an important class of antibiotics widely used in both human and 
animal medicine.112 This class of antibiotics prevents bacterial growth by interacting with 
the ribosomal 30S subunit and inhibiting protein synthesis. 112 The most important 
mechanism of resistance to tetracyclines results from acquisition of genetically mobile 
tetracycline resistance (tet) genes, which encode proteins that extrude tetracyclines, or 
confer ribosomal protection. 113 In Campylobacter spp., two mechanisms of tetracycline 
resistance have been reported, including i) ribosomal protection protein tet(O), and ii) 
endogenous efflux pumps. The Tet(O) protein can bind to a tetracycline molecule and 
promote its release from its target site on the ribosome.114 This gene can be found either 
on plasmids or in chromosome in both C. coli and C. jejuni. However, the G+C content 
(40%) of the tet(O) gene is higher than that of Campylobacter (~30%), indicating 
Campylobacter obtained the gene from other bacteria by horizontal gene transfer. The 
multidrug efflux pump CmeABC has been shown to contribute to both intrinsic and 
acquired resistance to tetracycline.62, 115 When CmeB was inactivated in C. jejuni 81-176 
(harboring tet(O) gene), the MIC of tetracycline decreased 8-fold (from 50 to 6.25 
ug/mL), indicating the role of CmeABC in mediating tetracycline resistance.62  
     Notably, a hypervirulent tetracycline resistant C. jejuni clone (named clone SA) has 
emerged as the predominant cause of Campylobacter-associated ovine abortions in the 
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United States during the last decade.116, 117 This clone was also associated with bovine 
and goat abortion cases in the United States.118 The recent clinical isolates of clone SA 
were all resistant to tetracycline due to a chromosomally encoded tet(O) gene.116, 117 The 
hypervirulence of clone SA in causing abortion was confirmed in a pregnant guinea pig 
model.119 Importantly, C. jejuni clone SA has been implicated in gastroenteritis cases of 
foodborne illness across the United States.118 Most of these foodborne illness outbreaks 
were traced to raw milk consumption, suggesting that clone SA was present in raw 
milk.118 Indeed, C. jejuni clone SA was identified in raw milk matched with the isolates 
from cattle farms and human patients, proving the transmission of C. jejuni clone SA 
from cattle to humans through raw milk. These findings strongly indicate that C. jejuni 
clone SA is an important food safety hazard in the U.S. and that cattle serve as a major 
reservoir for zoonotic transmission of this emergent clone from ruminants to humans.118 
6. Conclusive remarks 
     As a leading cause of bacterial foodborne illness worldwide, Campylobacter continues 
to pose a significant threat to food safety and public health.  As a foodborne pathogen, 
Campylobacter is exposed to antibiotics used for both animal agriculture and human 
medicine. Thus, the rising trend of antibiotic resistance in Campylobacter is likely driven 
by use of antibiotics. To acquire antibiotic resistance, Campylobacter may mutate 
antibiotic resistance genes such as the case with FQ and macrolide resistance, or acquire 
new antibiotic resistance determinants from other bacterial organisms by horizontal gene 
transfer, such as the case with erm(B) and cfr(C).  Interestingly, Campylobacter tends to 
acquire foreign antibiotic resistance genes from Gram-positive organisms, instead of 
Gram-negative bacteria. The exact reason and how this happens remains to be 
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investigated. Notably, a highly potent variant of the CmeABC efflux pump has emerged 
in C. jejuni, which confers enhanced resistance to multiple classes of antibiotics and 
illustrates the high adaptability of Campylobacter to antibiotic treatment.  Acquisition of 
antibiotic resistance mechanisms may influence the prevalence of specific 
Campylobacter clones or strains in their host species, and some examples are 
tetracycline-resistant C. jejuni clone SA causing sheep abortion and the C. coli clone of 
cattle origin that harbors the multidrug resistance gene cfr(C).  It is likely that 
Campylobacter will continue to evolve in response to antibiotic selection and it would 
not be surprising that new antibiotic resistance mechanisms continue to emerge in this 
foodborne pathogen. Understanding the epidemiology and mechanisms of antimicrobial 
resistance is necessary as it will help us to design strategies to mitigate antimicrobial 
resistance. 
 
References: 
 
1. Ruiz-Palacios GM. The health burden of Campylobacter infection and the impact 
of antimicrobial resistance: playing chicken. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 2007; 44: 701-3. 
 
2. Centers for Disease C, Prevention. Campylobacter jejuni infection associated with 
unpasteurized milk and cheese--Kansas, 2007. MMWR Morbidity and mortality weekly 
report 2009; 57: 1377-9. 
 
3. Stanley K, Jones K. Cattle and sheep farms as reservoirs of Campylobacter. 
Journal of applied microbiology 2003; 94 Suppl: 104S-13S. 
 
4. Allos BM. Campylobacter jejuni Infections: update on emerging issues and 
trends. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 2001; 32: 1201-6. 
 
5. Engberg J, Aarestrup FM, Taylor DE et al. Quinolone and macrolide resistance in 
Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. 
Emerging infectious diseases 2001; 7: 24-34. 
24 
 
 
 
 
6. Aarestrup FM, Engberg J. Antimicrobial resistance of thermophilic 
Campylobacter. Veterinary research 2001; 32: 311-21. 
 
7. CDC. Antibiotic Resistance Threats in the United States. 
http://wwwcdcgov/drugresistance/threat-report-2013/ 2013. 
 
8. Seliwiorstow T, Bare J, Van Damme I et al. Campylobacter carcass contamination 
throughout the slaughter process of Campylobacter-positive broiler batches. International 
journal of food microbiology 2015; 194: 25-31. 
 
9. Wong TL, Hollis L, Cornelius A et al. Prevalence, numbers, and subtypes of 
Campylobacter jejuni and Campylobacter coli in uncooked retail meat samples. Journal 
of food protection 2007; 70: 566-73. 
 
10. Hannon SJ, Taboada EN, Russell ML et al. Genomics-based molecular 
epidemiology of Campylobacter jejuni isolates from feedlot cattle and from people in 
Alberta, Canada. Journal of clinical microbiology 2009; 47: 410-20. 
 
11. Mullner P, Shadbolt T, Collins-Emerson JM et al. Molecular and spatial 
epidemiology of human campylobacteriosis: source association and genotype-related risk 
factors. Epidemiology and infection 2010; 138: 1372-83. 
 
12. Clark CG, Price L, Ahmed R et al. Characterization of waterborne outbreak-
associated Campylobacter jejuni, Walkerton, Ontario. Emerging infectious diseases 2003; 
9: 1232-41. 
 
13. Wilson DJ, Gabriel E, Leatherbarrow AJ et al. Tracing the source of 
campylobacteriosis. PLoS genetics 2008; 4: e1000203. 
 
14. Heuvelink AE, van Heerwaarden C, Zwartkruis-Nahuis A et al. Two outbreaks of 
campylobacteriosis associated with the consumption of raw cows' milk. International 
journal of food microbiology 2009; 134: 70-4. 
 
15. Lejeune JT, Rajala-Schultz PJ. Food safety: unpasteurized milk: a continued 
public health threat. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America 2009; 48: 93-100. 
 
16. Newkirk R, Hedberg C, Bender J. Establishing a milkborne disease outbreak 
profile: potential food defense implications. Foodborne pathogens and disease 2011; 8: 
433-7. 
 
17. Jacobs-Reitsma W, U. Lyhs, and J. Wagenaar. Campylobacter in the Food 
Supply. ASM Press, Washington, DC 2008: 627-44. 
 
25 
 
 
 
18. McDermott PF, Bodeis SM, Aarestrup FM et al. Development of a standardized 
susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, 
doxycycline, erythromycin, gentamicin, and meropenem. Microbial drug resistance 
2004; 10: 124-31. 
 
19. Luangtongkum T, Morishita TY, El-Tayeb AB et al. Comparison of antimicrobial 
susceptibility testing of Campylobacter spp. by the agar dilution and the agar disk 
diffusion methods. Journal of clinical microbiology 2007; 45: 590-4. 
 
20. Luber P, Bartelt E, Genschow E et al. Comparison of broth microdilution, E Test, 
and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni 
and Campylobacter coli. Journal of clinical microbiology 2003; 41: 1062-8. 
 
21. Sierra-Arguello YM, Perdoncini G, Morgan RB et al. Fluoroquinolone and 
macrolide resistance in Campylobacter jejuni isolated from broiler slaughterhouses in 
southern Brazil. Avian pathology : journal of the WVPA 2016; 45: 66-72. 
 
22. Nguyen TN, Hotzel H, El-Adawy H et al. Genotyping and antibiotic resistance of 
thermophilic Campylobacter isolated from chicken and pig meat in Vietnam. Gut 
pathogens 2016; 8: 19. 
 
23. Padungton P, Kaneene JB. Campylobacter spp in human, chickens, pigs and their 
antimicrobial resistance. The Journal of veterinary medical science 2003; 65: 161-70. 
 
24. Saenz Y, Zarazaga M, Lantero M et al. Antibiotic resistance in Campylobacter 
strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrobial 
agents and chemotherapy 2000; 44: 267-71. 
 
25. Endtz HP, Ruijs GJ, van Klingeren B et al. Quinolone resistance in campylobacter 
isolated from man and poultry following the introduction of fluoroquinolones in 
veterinary medicine. The Journal of antimicrobial chemotherapy 1991; 27: 199-208. 
 
26. Humphrey TJ, Jorgensen F, Frost JA et al. Prevalence and subtypes of 
ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, 
and after treatment with fluoroquinolones. Antimicrobial agents and chemotherapy 2005; 
49: 690-8. 
 
27. van Boven M, Veldman KT, de Jong MC et al. Rapid selection of quinolone 
resistance in Campylobacter jejuni but not in Escherichia coli in individually housed 
broilers. The Journal of antimicrobial chemotherapy 2003; 52: 719-23. 
 
28. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in 
Campylobacter jejuni, Pennsylvania, USA,1982-2001. Emerging infectious diseases 
2002; 8: 1501-3. 
 
26 
 
 
 
29. Zhang Q, Lin J, Pereira S. Fluoroquinolone-resistant Campylobacter in animal 
reservoirs: dynamics of development, resistance mechanisms and ecological fitness. 
Animal health research reviews / Conference of Research Workers in Animal Diseases 
2003; 4: 63-71. 
 
30. McDermott PF, Bodeis SM, English LL et al. Ciprofloxacin resistance in 
Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. The 
Journal of infectious diseases 2002; 185: 837-40. 
 
31. Hoge CW, Gambel JM, Srijan A et al. Trends in antibiotic resistance among 
diarrheal pathogens isolated in Thailand over 15 years. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 1998; 26: 341-5. 
 
32. Zhou J, Zhang M, Yang W et al. A seventeen-year observation of the 
antimicrobial susceptibility of clinical Campylobacter jejuni and the molecular 
mechanisms of erythromycin-resistant isolates in Beijing, China. International journal of 
infectious diseases : IJID : official publication of the International Society for Infectious 
Diseases 2016; 42: 28-33. 
 
33. Wang Y, Dong Y, Deng F et al. Species shift and multidrug resistance of 
Campylobacter from chicken and swine, China, 2008-14. The Journal of antimicrobial 
chemotherapy 2016; 71: 666-9. 
 
34. Gallay A, Prouzet-Mauleon V, Kempf I et al. Campylobacter antimicrobial drug 
resistance among humans, broiler chickens, and pigs, France. Emerging infectious 
diseases 2007; 13: 259-66. 
 
35. Lucey B, Cryan B, O'Halloran F et al. Trends in antimicrobial susceptibility 
among isolates of Campylobacter species in Ireland and the emergence of resistance to 
ciprofloxacin. The Veterinary record 2002; 151: 317-20. 
 
36. Pezzotti G, Serafin A, Luzzi I et al. Occurrence and resistance to antibiotics of 
Campylobacter jejuni and Campylobacter coli in animals and meat in northeastern Italy. 
International journal of food microbiology 2003; 82: 281-7. 
 
37. Cha W, Mosci R, Wengert SL et al. Antimicrobial Susceptibility Profiles of 
Human Campylobacter jejuni Isolates and Association with Phylogenetic Lineages. 
Frontiers in microbiology 2016; 7: 589. 
 
38. USDA. Salmonella, Listeria, and Camplobacter on U.S. Dairy Operation, 1996-
2007. USDA-APHIS-VS, CEAH Fort Collins, CO #5780311 2011. 
 
39. Papavasileiou E, Voyatzi A, Papavasileiou K et al. Antimicrobial susceptibilities 
of Campylobacter jejuni isolates from hospitalized children in Athens, Greece, collected 
during 2004-2005. European journal of epidemiology 2007; 22: 77-8. 
 
27 
 
 
 
40. Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and 
Campylobacter coli. The Journal of antimicrobial chemotherapy 2006; 58: 243-55. 
 
41. Bardon J, Kolar M, Cekanova L et al. Prevalence of Campylobacter jejuni and its 
resistance to antibiotics in poultry in the Czech Republic. Zoonoses and public health 
2009; 56: 111-6. 
 
42. Li B, Ma L, Li Y et al. Antimicrobial Resistance of Campylobacter Species 
Isolated from Broilers in Live Bird Markets in Shanghai, China. Foodborne pathogens 
and disease 2016. 
 
43. Shobo CO, Bester LA, Baijnath S et al. Antibiotic resistance profiles of 
Campylobacter species in the South Africa private health care sector. Journal of infection 
in developing countries 2016; 10: 1214-21. 
 
44. Singh S, Mittal A. Transmembrane Domain Lengths Serve as Signatures of 
Organismal Complexity and Viral Transport Mechanisms. Scientific reports 2016; 6: 
22352. 
 
45. Ma L, Wang Y, Shen J et al. Tracking Campylobacter contamination along a 
broiler chicken production chain from the farm level to retail in China. International 
journal of food microbiology 2014; 181: 77-84. 
 
46. Li B, Ma L, Li Y et al. Antimicrobial Resistance of Campylobacter Species 
Isolated from Broilers in Live Bird Markets in Shanghai, China. Foodborne pathogens 
and disease 2017; 14: 96-102. 
 
47. Zhao S, Young SR, Tong E et al. Antimicrobial resistance of Campylobacter 
isolates from retail meat in the United States between 2002 and 2007. Applied and 
environmental microbiology 2010; 76: 7949-56. 
 
48. Andersson MI, MacGowan AP. Development of the quinolones. The Journal of 
antimicrobial chemotherapy 2003; 51 Suppl 1: 1-11. 
 
49. Jacoby GA. Mechanisms of resistance to quinolones. Clinical infectious diseases : 
an official publication of the Infectious Diseases Society of America 2005; 41 Suppl 2: 
S120-6. 
 
50. Martin-Gutierrez G, Rodriguez-Martinez JM, Pascual A et al. Plasmidic qnr genes 
confer clinical resistance to ciprofloxacin under urinary tract physiological conditions. 
Antimicrobial agents and chemotherapy 2017. 
 
51. Payot S, Bolla JM, Corcoran D et al. Mechanisms of fluoroquinolone and 
macrolide resistance in Campylobacter spp. Microbes and infection / Institut Pasteur 
2006; 8: 1967-71. 
 
28 
 
 
 
52. Bachoual R, Ouabdesselam S, Mory F et al. Single or double mutational 
alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni 
and Campylobacter coli. Microbial drug resistance 2001; 7: 257-61. 
 
53. Payot S, Cloeckaert A, Chaslus-Dancla E. Selection and characterization of 
fluoroquinolone-resistant mutants of Campylobacter jejuni using enrofloxacin. Microbial 
drug resistance 2002; 8: 335-43. 
 
54. Piddock LJ, Ricci V, Pumbwe L et al. Fluoroquinolone resistance in 
Campylobacter species from man and animals: detection of mutations in topoisomerase 
genes. The Journal of antimicrobial chemotherapy 2003; 51: 19-26. 
 
55. Friedman SM, Lu T, Drlica K. Mutation in the DNA gyrase A Gene of 
Escherichia coli that expands the quinolone resistance-determining region. Antimicrobial 
agents and chemotherapy 2001; 45: 2378-80. 
 
56. Luo N, Sahin O, Lin J et al. In vivo selection of Campylobacter isolates with high 
levels of fluoroquinolone resistance associated with gyrA mutations and the function of 
the CmeABC efflux pump. Antimicrobial agents and chemotherapy 2003; 47: 390-4. 
 
57. Wang Y, Huang WM, Taylor DE. Cloning and nucleotide sequence of the 
Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. 
Antimicrobial agents and chemotherapy 1993; 37: 457-63. 
 
58. Yan M, Sahin O, Lin J et al. Role of the CmeABC efflux pump in the emergence 
of fluoroquinolone-resistant Campylobacter under selection pressure. The Journal of 
antimicrobial chemotherapy 2006; 58: 1154-9. 
 
59. Gootz TD, Martin BA. Characterization of high-level quinolone resistance in 
Campylobacter jejuni. Antimicrobial agents and chemotherapy 1991; 35: 840-5. 
 
60. Ruiz J, Goni P, Marco F et al. Increased resistance to quinolones in 
Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-resistant 
clinical isolates. Microbiology and immunology 1998; 42: 223-6. 
 
61. Ge B, McDermott PF, White DG et al. Role of efflux pumps and topoisomerase 
mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. 
Antimicrobial agents and chemotherapy 2005; 49: 3347-54. 
 
62. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in 
Campylobacter jejuni. Antimicrobial agents and chemotherapy 2002; 46: 2124-31. 
 
63. Lin J, Akiba M, Sahin O et al. CmeR functions as a transcriptional repressor for 
the multidrug efflux pump CmeABC in Campylobacter jejuni. Antimicrobial agents and 
chemotherapy 2005; 49: 1067-75. 
 
29 
 
 
 
64. Yao H, Shen Z, Wang Y et al. Emergence of a Potent Multidrug Efflux Pump 
Variant That Enhances Campylobacter Resistance to Multiple Antibiotics. mBio 2016; 7. 
 
65. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, 
lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. 
Journal of molecular biology 2003; 330: 1005-14. 
 
66. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of 
the resistance elements and their clinical implications. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 2002; 34: 482-92. 
 
67. Vacher S, Menard A, Bernard E et al. PCR-restriction fragment length 
polymorphism analysis for detection of point mutations associated with macrolide 
resistance in Campylobacter spp. Antimicrobial agents and chemotherapy 2003; 47: 
1125-8. 
 
68. Vacher S, Menard A, Bernard E et al. Detection of mutations associated with 
macrolide resistance in thermophilic Campylobacter spp. by real-time PCR. Microbial 
drug resistance 2005; 11: 40-7. 
 
69. Jensen LB, Aarestrup FM. Macrolide resistance in Campylobacter coli of animal 
origin in Denmark. Antimicrobial agents and chemotherapy 2001; 45: 371-2. 
 
70. Gibreel A, Kos VN, Keelan M et al. Macrolide resistance in Campylobacter jejuni 
and Campylobacter coli: molecular mechanism and stability of the resistance phenotype. 
Antimicrobial agents and chemotherapy 2005; 49: 2753-9. 
 
71. Niwa H, Chuma T, Okamoto K et al. Rapid detection of mutations associated with 
resistance to erythromycin in Campylobacter jejuni/coli by PCR and line probe assay. 
International journal of antimicrobial agents 2001; 18: 359-64. 
 
72. Ohno H, Wachino J, Saito R et al. A Highly Macrolide-Resistant Campylobacter 
jejuni Strain with Rare A2074T Mutations in 23S rRNA Genes. Antimicrobial agents and 
chemotherapy 2016; 60: 2580-1. 
 
73. Corcoran D, Quinn T, Cotter L et al. An investigation of the molecular 
mechanisms contributing to high-level erythromycin resistance in Campylobacter. 
International journal of antimicrobial agents 2006; 27: 40-5. 
 
74. Chittum HS, Champney WS. Ribosomal protein gene sequence changes in 
erythromycin-resistant mutants of Escherichia coli. Journal of bacteriology 1994; 176: 
6192-8. 
 
75. Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of 
macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe 
and North America. Antimicrobial agents and chemotherapy 2000; 44: 3395-401. 
30 
 
 
 
 
76. Malbruny B, Nagai K, Coquemont M et al. Resistance to macrolides in clinical 
isolates of Streptococcus pyogenes due to ribosomal mutations. The Journal of 
antimicrobial chemotherapy 2002; 49: 935-9. 
 
77. Cagliero C, Mouline C, Cloeckaert A et al. Synergy between efflux pump 
CmeABC and modifications in ribosomal proteins L4 and L22 in conferring macrolide 
resistance in Campylobacter jejuni and Campylobacter coli. Antimicrobial agents and 
chemotherapy 2006; 50: 3893-6. 
 
78. Doktor SZ, Shortridge VD, Beyer JM et al. Epidemiology of macrolide and/or 
lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal 
mutations. Diagnostic microbiology and infectious disease 2004; 49: 47-52. 
 
79. Lehtopolku M, Kotilainen P, Haanpera-Heikkinen M et al. Ribosomal mutations 
as the main cause of macrolide resistance in Campylobacter jejuni and Campylobacter 
coli. Antimicrobial agents and chemotherapy 2011; 55: 5939-41. 
 
80. Caldwell DB, Wang Y, Lin J. Development, stability, and molecular mechanisms 
of macrolide resistance in Campylobacter jejuni. Antimicrobial agents and chemotherapy 
2008; 52: 3947-54. 
 
81. Qin S, Wang Y, Zhang Q et al. Report of ribosomal RNA methylase gene erm(B) 
in multidrug-resistant Campylobacter coli. The Journal of antimicrobial chemotherapy 
2014; 69: 964-8. 
 
82. Florez-Cuadrado D, Ugarte-Ruiz M, Quesada A et al. Description of an erm(B)-
carrying Campylobacter coli isolate in Europe. The Journal of antimicrobial 
chemotherapy 2016; 71: 841-3. 
 
83. Deng F, Wang Y, Zhang Y et al. Characterization of the genetic environment of 
the ribosomal RNA methylase gene erm(B) in Campylobacter jejuni. The Journal of 
antimicrobial chemotherapy 2015; 70: 613-5. 
 
84. Cagliero C, Mouline C, Payot S et al. Involvement of the CmeABC efflux pump 
in the macrolide resistance of Campylobacter coli. The Journal of antimicrobial 
chemotherapy 2005; 56: 948-50. 
 
85. Mamelli L, Prouzet-Mauleon V, Pages JM et al. Molecular basis of macrolide 
resistance in Campylobacter: role of efflux pumps and target mutations. The Journal of 
antimicrobial chemotherapy 2005; 56: 491-7. 
 
86. Payot S, Avrain L, Magras C et al. Relative contribution of target gene mutation 
and efflux to fluoroquinolone and erythromycin resistance, in French poultry and pig 
isolates of Campylobacter coli. International journal of antimicrobial agents 2004; 23: 
468-72. 
31 
 
 
 
 
87. Mamelli L, Amoros JP, Pages JM et al. A phenylalanine-arginine beta-
naphthylamide sensitive multidrug efflux pump involved in intrinsic and acquired 
resistance of Campylobacter to macrolides. International journal of antimicrobial agents 
2003; 22: 237-41. 
 
88. Lomovskaya O, Warren MS, Lee A et al. Identification and characterization of 
inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents 
for combination therapy. Antimicrobial agents and chemotherapy 2001; 45: 105-16. 
 
89. Syriopoulou VP, Harding AL, Goldmann DA et al. In vitro antibacterial activity 
of fluorinated analogs of chloramphenicol and thiamphenicol. Antimicrobial agents and 
chemotherapy 1981; 19: 294-7. 
 
90. Schwarz S, Kehrenberg C, Doublet B et al. Molecular basis of bacterial resistance 
to chloramphenicol and florfenicol. FEMS microbiology reviews 2004; 28: 519-42. 
 
91. Kehrenberg C, Schwarz S, Jacobsen L et al. A new mechanism for 
chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal 
RNA at A2503. Molecular microbiology 2005; 57: 1064-73. 
 
92. Long KS, Poehlsgaard J, Kehrenberg C et al. The Cfr rRNA methyltransferase 
confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and 
Streptogramin A antibiotics. Antimicrobial agents and chemotherapy 2006; 50: 2500-5. 
 
93. Schwarz S, Werckenthin C, Kehrenberg C. Identification of a plasmid-borne 
chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrobial 
agents and chemotherapy 2000; 44: 2530-3. 
 
94. Liu Y, Wang Y, Schwarz S et al. Transferable multiresistance plasmids carrying 
cfr in Enterococcus spp. from swine and farm environment. Antimicrobial agents and 
chemotherapy 2013; 57: 42-8. 
 
95. Dai L, Wu CM, Wang MG et al. First report of the multidrug resistance gene cfr 
and the phenicol resistance gene fexA in a Bacillus strain from swine feces. 
Antimicrobial agents and chemotherapy 2010; 54: 3953-5. 
 
96. Wang Y, Wang Y, Schwarz S et al. Detection of the staphylococcal 
multiresistance gene cfr in Macrococcus caseolyticus and Jeotgalicoccus pinnipedialis. 
The Journal of antimicrobial chemotherapy 2012; 67: 1824-7. 
 
97. Wang Y, He T, Schwarz S et al. Detection of the staphylococcal multiresistance 
gene cfr in Escherichia coli of domestic-animal origin. The Journal of antimicrobial 
chemotherapy 2012; 67: 1094-8. 
 
32 
 
 
 
98. Zhang R, Sun B, Wang Y et al. Characterization of a cfr-Carrying Plasmid from 
Porcine Escherichia coli That Closely Resembles Plasmid pEA3 from the Plant Pathogen 
Erwinia amylovora. Antimicrobial agents and chemotherapy 2015; 60: 658-61. 
 
99. Li D, Wu C, Wang Y et al. Identification of multiresistance gene cfr in 
methicillin-resistant Staphylococcus aureus from pigs: plasmid location and integration 
into a staphylococcal cassette chromosome mec complex. Antimicrobial agents and 
chemotherapy 2015; 59: 3641-4. 
 
100. Liu Y, Wang Y, Dai L et al. First report of multiresistance gene cfr in 
Enterococcus species casseliflavus and gallinarum of swine origin. Veterinary 
microbiology 2014; 170: 352-7. 
101. Wang Y, Li D, Song L et al. First report of the multiresistance gene cfr in 
Streptococcus suis. Antimicrobial agents and chemotherapy 2013; 57: 4061-3. 
 
102. Deshpande LM, Ashcraft DS, Kahn HP et al. Detection of a New cfr-Like Gene, 
cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the 
United States as Part of the SENTRY Antimicrobial Surveillance Program. Antimicrobial 
agents and chemotherapy 2015; 59: 6256-61. 
 
103. Hansen LH, Vester B. A cfr-like gene from Clostridium difficile confers multiple 
antibiotic resistance by the same mechanism as the cfr gene. Antimicrobial agents and 
chemotherapy 2015; 59: 5841-3. 
 
104. Tang Y, Dai L, Sahin O et al. Emergence of a plasmid-borne multidrug resistance 
gene cfr(C) in foodborne pathogen Campylobacter. The Journal of antimicrobial 
chemotherapy 2017. 
105. Ma L, Shen Z, Naren G et al. Identification of a novel G2073A mutation in 23S 
rRNA in amphenicol-selected mutants of Campylobacter jejuni. PloS one 2014; 9: 
e94503. 
 
106. Arcangioli MA, Leroy-Setrin S, Martel JL et al. A new chloramphenicol and 
florfenicol resistance gene flanked by two integron structures in Salmonella typhimurium 
DT104. FEMS microbiology letters 1999; 174: 327-32. 
 
107. Frye JG, Lindsey RL, Meinersmann RJ et al. Related antimicrobial resistance 
genes detected in different bacterial species co-isolated from swine fecal samples. 
Foodborne pathogens and disease 2011; 8: 663-79. 
 
108. Kim E, Aoki T. Sequence analysis of the florfenicol resistance gene encoded in 
the transferable R-plasmid of a fish pathogen, Pasteurella piscicida. Microbiology and 
immunology 1996; 40: 665-9. 
 
109. Bolton LF, Kelley LC, Lee MD et al. Detection of multidrug-resistant Salmonella 
enterica serotype typhimurium DT104 based on a gene which confers cross-resistance to 
florfenicol and chloramphenicol. Journal of clinical microbiology 1999; 37: 1348-51. 
33 
 
 
 
 
110. Liu H, Wang Y, Wu C et al. A novel phenicol exporter gene, fexB, found in 
enterococci of animal origin. The Journal of antimicrobial chemotherapy 2012; 67: 322-
5. 
 
111. Gomez-Sanz E, Kadlec K, Fessler AT et al. A novel fexA variant from a canine 
Staphylococcus pseudintermedius isolate that does not confer florfenicol resistance. 
Antimicrobial agents and chemotherapy 2013; 57: 5763-6. 
 
112. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Current 
opinion in pharmacology 2001; 1: 464-9. 
 
113. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, 
molecular biology, and epidemiology of bacterial resistance. Microbiology and molecular 
biology reviews : MMBR 2001; 65: 232-60 ; second page, table of contents. 
 
114. Connell SR, Trieber CA, Dinos GP et al. Mechanism of Tet(O)-mediated 
tetracycline resistance. The EMBO journal 2003; 22: 945-53. 
 
115. Gibreel A, Wetsch NM, Taylor DE. Contribution of the CmeABC efflux pump to 
macrolide and tetracycline resistance in Campylobacter jejuni. Antimicrobial agents and 
chemotherapy 2007; 51: 3212-6. 
 
116. Sahin O, Plummer PJ, Jordan DM et al. Emergence of a tetracycline-resistant 
Campylobacter jejuni clone associated with outbreaks of ovine abortion in the United 
States. Journal of clinical microbiology 2008; 46: 1663-71. 
 
117. Wu Z, Sippy R, Sahin O et al. Genetic diversity and antimicrobial susceptibility 
of Campylobacter jejuni isolates associated with sheep abortion in the United States and 
Great Britain. Journal of clinical microbiology 2014; 52: 1853-61. 
 
118. Sahin O, Fitzgerald C, Stroika S et al. Molecular evidence for zoonotic 
transmission of an emergent, highly pathogenic Campylobacter jejuni clone in the United 
States. Journal of clinical microbiology 2012; 50: 680-7. 
 
119. Burrough ER, Sahin O, Plummer PJ et al. Pathogenicity of an emergent, ovine 
abortifacient Campylobacter jejuni clone orally inoculated into pregnant guinea pigs. 
American journal of veterinary research 2009; 70: 1269-76. 
 
 
 
34 
 
 
 
CHAPTER 3. PREVALENCE AND MOLECULAR EPIDEMIOLOGY OF A 
HYPERVIRULENT CAMPYLOBACTER JEJUNI CLONE IN BEEF AND DAIRY 
CATTLE IN THE UNITED STATES 
A paper to be submitted to Applied and Environmental Microbiology  
 
Yizhi Tanga, Rick Meinersmannc, Orhan Sahina,b, Zuowei Wua, Lei Daia, James Carlsond, 
Jeff LeJeunee and Qijing Zhanga#. 
Departments of aVeterinary Microbiology and Preventive Medicine, and bVeterinary 
Diagnostic and Production Animal Medicine, Ames, IA, USA; cBEAR-RU,  USDA ARS, 
Athens, GA;  dNational Wildlife Research Center, USDA APHIS, Fort Collins, CO; 
eFood Animal Health Research Program, Ohio State University, Wooster, OH.  
 
Running Title: Prevalence of Campylobacter jejuni clone SA in cattle 
 
#To whom correspondence should be addressed:  
Department of Veterinary Microbiology and Preventive Medicine  
Iowa State University 
Ames, Iowa 50010, USA 
zhang123@iastate.edu 
 
 
 
 
35 
 
 
 
Abstract 
     Campylobacter jejuni is a significant concern for ruminant health and food safety. 
Recently, a highly pathogenic C. jejuni clone (named SA) has emerged as the 
predominant cause of ruminant abortion and a significant cause of foodborne illnesses in 
the United States. Despite recent advances in understanding the pathogenesis of clone 
SA, little is known about its distribution and epidemiological features in cattle, which 
hinders the control of this emergent pathogen. Here we describe a prospective study on 
the prevalence of C. jejuni clone SA in 35 feedlots in 5 states and a retrospective analysis 
of clone SA in dairy cows collected by NAHMS Dairy Studies 2002, 2007 and 2014. In 
feedlot cattle, the overall prevalence of Campylobacter was 72.2% and 82.1% of the 
isolates were C. jejuni. Clone SA accounted for 5.8% of the total C. jejuni isolates, but its 
prevalence varied with feedlots and states.  Interestingly, starlings on the feedlots 
harbored C. jejuni including clone SA, suggesting it plays a role in the transmission of 
Campylobacter. In dairy cattle, the overall prevalence of clone SA was 7.2%, but a 
declining trend in the prevalence was detected from 2002 to 2014. Whole genomic 
sequence analysis of dairy clone SA isolates revealed that it is genetically stable over the 
years and most of the isolates carried the tetracycline resistance tet(O) gene in the 
chromosome. These findings indicate that clone SA is widely distributed in both beef and 
dairy cattle and provide new insights into the molecular epidemiology of clone SA in 
ruminants.  
Importance 
     C. jejuni clone SA is a major cause of ruminant abortion and an emerging threat to food 
safety. Cattle serve as a major reservoir for this pathogenic organism, but there is a major 
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gap in our knowledge about the epidemiology of clone SA in beef and dairy cattle. By 
taking advantage of surveillance studies conducted on a national scale, this manuscript 
describes for the first time the wide but variable distribution of clone SA in feedlot cattle 
and dairy cow in the U.S. Additionally, the work revealed important genomic features of 
clone SA isolates. These findings provide critically needed information for the 
development of pre-harvest interventions to control the prevalence and transmission of this 
zoonotic pathogen. Control of C. jejuni clone SA will benefit both animal health and public 
health as it is a zoonotic pathogen causing diseases in both ruminants and humans. 
 
Introduction 
     Campylobacter jejuni is a major zoonotic bacterial pathogen and primarily causes 
foodborne enteritis in humans (1, 2). The organism is widely distributed in a broad range 
of animal species including livestock, poultry and wildlife, and is transmitted to humans 
mainly via the consumption of contaminated food, water and milk (2). As reported by the 
Centers for Disease Control and Prevention (CDC)’s FoodNet surveillance program in 
2016, Campylobacter ranked in the second place (12.97 per 100,000 population) among 
the causes of laboratory-confirmed bacterial food-borne illnesses in the United States (3). 
Poultry, especially market-age broiler chickens, are frequently colonized by C. jejuni, 
resulting in carcass contamination in processing plants (4, 5). Consequently, poultry meat 
is considered a major source of infection for human campylobacteriosis.  
     In addition to poultry, cattle also serves as an important reservoir for Campylobacter. 
Bovine Campylobacter contributes significantly to both outbreak and sporadic cases of 
campylobacteriosis in humans (6, 7). Cattle Campylobacter can be transmitted to humans 
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via multiple transmission routes including direct contact (e.g. petting zoo and occupational 
exposure), consumption of unpasteurized milk (and associated dairy products), and 
environmental contamination (water, produce, etc.) (8-10). Molecular typing of C. jejuni 
isolates using multilocus sequence typing (MLST) attributed approximately 40% of 
sporadic human cases to cattle sources in the United Kingdom (11). The contribution of 
bovine Campylobacter to outbreaks of human campylobacteriosis is even more prominent 
because Campylobacter from cattle feces frequently contaminates raw milk (9, 12-14). 
Ruminant Campylobacter may also contaminate water supplies via agricultural runoff, 
leading to large waterborne outbreaks (8). Of note, red meat is infrequently contaminated 
by Campylobacter (15) and does not appear to play a major role in the transmission of 
Campylobacter to humans. Additionally, ruminants are an integral part of Campylobacter 
ecology and may serve as a source of Campylobacter transmission to the environment and 
other farm animals, such as poultry.  Thus, poultry and cattle are the two most important 
animal reservoirs for this zoonotic pathogen. 
     Campylobacter is highly prevalent in both beef and dairy cattle in the U.S. and 
worldwide (10, 16-20). In cattle, Campylobacter is mainly carried in the intestinal tract and 
less frequently can be isolated from the rumen, gall bladder, and bile (11, 21). The 
predominant Campylobacter species isolated from cattle is C. jejuni, followed by C. coli 
(10, 22-25). Isolation rates vary with country, herd size and type, age of animals, season, 
and confinement levels (10, 25). In the U.S., several nationwide surveillance studies of 
cattle (NAHMS Dairy 1996, 2002, 2007, and Feedlot’99) indicated a fecal carriage rate of 
approximately 15-50% with the majority of the operations (herds/farms/feedlots) being 
tested positive for Campylobacter (17, 24, 26). Several other studies conducted in different 
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states in the U.S. also revealed a similar range of prevalence (between 20-60% at the fecal 
sample level) of Campylobacter in feedlot cattle and dairy cattle (18, 22, 23, 25, 27). 
     Although Campylobacter mainly colonizes in the gastrointestinal tract in animals, it 
may translocate across the intestinal epithelial barrier, leading to systemic infection, such 
as bacteremia and abortion in ruminants and occasionally in humans (28). Indeed, 
Campylobacter infection is one of the most prevalent causes of ovine abortion in the United 
States and worldwide, with an overall abortion rate of 5% to 50% (average, 23.2%) in 
affected flocks (29). Historically, C. fetus subsp. fetus was the major cause of 
Campylobacter-associated ovine abortion. However, studies conducted during late 1980s 
and early 1990s in the United States revealed a progressive increase in the isolation of C. 
jejuni from aborted sheep placentas (30, 31). Recently, our studies demonstrated that a 
single hypervirulent tetracycline-resistant C. jejuni clone (named clone SA) has emerged 
as the predominant cause of Campylobacter-associated ovine abortions in the United States 
during the last decade (29, 32). Additionally, clone SA was also associated with bovine and 
goat abortion cases in the United States (33). Importantly, C. jejuni clone SA has been 
implicated in a number cases of foodborne illnesses, both outbreaks and sporadic cases, in 
the United States (33). These findings clearly indicated that C. jejuni clone SA is an 
important pathogen for both animal health and food safety in the United States and that 
cattle serve as a major reservoir for its zoonotic transmission.  
     Despite its obvious significance to human and ruminant health in general, little 
information is available about the distribution of C. jejuni clone SA in beef and dairy cattle, 
which represents an important knowledge gap in our understanding of the overall 
epidemiology and this zoonotic risk. To close this knowledge gap and facilitate the control 
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of C. jejuni clone SA and its zoonotic transmission, we conducted a cross-sectional study, 
with repeated sampling of 35 feedlots located in various geographical regions on two 
different occasions.  Additionally, we analyzed the Campylobacter isolates in the 
collections of NAHMS (National Animal Health Monitoring System) Dairy 2002, 2007 
and 2014 studies (17, 34).  The purposes of this study were to: 1) investigate the overall 
prevalence of Campylobacter in feedlot cattle and evaluate the effect of starling 
intervention on the occurrence and spread of Campylobacter in feedlot operation, 2) 
determine the occurrence and distribution of C. jejuni clone SA in feedlot and dairy cattle. 
Materials and Methods  
Sample collection and bacterial isolation  
     In the prospective cross-sectional repeated study, a total of 3,184 cattle fecal samples 
were collected from 35 different feedlot herds located in Iowa, Texas, Colorado, Missouri 
and Kansas on two different occasions during December 2012 to March 2013. Collection 
of cattle fecal samples followed methods that have been described previously (35). A 
sample was collected from a fecal pat only after a cow was observed defecating. Freshly 
voided fecal pats were scraped with a sterile cotton tipped swab and the swab was 
immediately placed in 10 ml glass tubes containing Campylobacter Thioglycollate Broth 
(CAMPY-THIO). All cattle fecal samples were shipped priority overnight to the testing 
laboratory. Only samples received by the laboratories within 24 hours of the date of 
collection were cultured for Campylobacter. Of note, the fecal samples were collected 
during a European starling intervention program taking place on the farms (36). In order 
to determine the effect of this control program on Campylobacter prevalence, 
approximately one-half of the samples were obtained before and the other half was 
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obtained after the intervention. In addition to cattle fecal specimens, 150 fecal samples 
from starlings present on 7 feedlots (from which post-intervention cattle samples were 
also tested concurrently) were sampled for Campylobacter presence during February and 
March of 2013. Starling feces (a few grams per bird or droppings) were placed into the 
same transport media and shipped to the laboratory as described for the cattle feces. In 
the laboratory, 1 mL of the transport media containing a fecal swab was added into a 
tubes containing 9 mL of Campylobacter enrichment broth, which was then incubated at 
42 °C for 48 h under microaerobic conditions (5% O2, 10% CO2, and 85% N2). The 
enrichment medium was Mueller–Hinton (MH) broth supplemented with Campylobacter-
specific selective agents (SR084E and SR117E; Oxoid). From the enrichment culture, an 
inoculum of 100 µL was streaked onto a MH agar plate containing the same supplements, 
which was further incubated for 48 h at 42 °C under microaerobic conditions. A single 
Campylobacter-like colony from each sample was subpassaged onto a plain MH agar 
plate and the pure culture was stored in glycerol stocks at -80 °C until further use.  
     In order to determine the distribution of C. jejuni clone SA in dairy cattle feces, 
retrospective Campylobacter isolates collected by NAHMS Dairy 2002, 2007 and 2014 
studies (34, 37) were analyzed for clone SA. In total, 205, 627, and 576 C. jejuni isolates 
from Dairy 2002, 2007 and 2014 studies, respectively, were screened for putative clone 
SA using a specific PCR (see below). Further confirmation of the putative clone SA 
isolates was performed via whole genome sequence analysis.  
DNA extraction and PCR identification  
     DNA was extracted from Campylobacter colonies using the single-cell lysis buffer 
(38) and was used as template for PCR reactions. In order to detect and/or differentiate C. 
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jejuni, C. coli, and C. jejuni clone SA, three sets of previously published primers were 
used. The first primer pair (CCCJ-F: 5’-AAT CTA ATG GCT TAA CCA TTA-3’; CCCJ-
R: 5’-GTA ACT AGT TTA GTA TTC CGG-3’), targeting 16S rRNA, was designed to co-
identify C. jejuni and C. coli (39). The second primer pair (mapA-F: 5’-GAG TGC TTG 
TGC AAC TAA AC-3’; mapA-R: 5-’ATA GCA TCT TGA GTT GCT CC-3’) was specific 
for C. jejuni (40). The third PCR primer pair (CJSA_1356F: 5′-TCC CAT TTG GAT GTT 
GTT GA-3′; CJSA_1356R: 5′-CAG AAC CTG GCC ACA AAC TT-3′) was used for 
identification of putative C. jejuni clone SA as described previously (41). C. jejuni 
IA3902, a clinical isolate of clone SA, were used as positive controls for the PCR, 
whereas reactions with no DNA template were used as negative controls. Each PCR 
amplification was carried out in a 25-μl volume containing 16 µL of distilled water, 2.0 
µL of template DNA, 10 pmol of each primer, 5 μl of GoTaq (Promega) green master mix 
following the cycling conditions described previously (39-41).  
Pulsed-field gel electrophoresis (PFGE) 
     PFGE analysis of C. jejuni isolates was performed using KpnI following the PulseNet 
protocol (Centers for Disease Control and Prevention; CDC) with minor modifications 
(29). Briefly, fresh cultures of Campylobacter were embedded in 1% Seakem Gold 
agarose (Fisher Scientific, Fair Lawn, NJ) and lysed with proteinase K for 1 h at 55 °C in 
a water bath shaker. The gel plugs were digested with KpnI for 4 h at 37 °C. Digested 
plugs were embedded into 1% agarose and separated by electrophoresis in 0.5  TBE 
buffer (Promega) at 14 °C for 18 h using a Chef Mapper electrophoresis system (Bio-
Rad, Herculules, CA). Gels were stained with ethidium bromide for 30 min and then 
photographed by using ChemilmagerTM 5500 (Alpha Innotech, CA, USA). The PFGE 
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patterns were analyzed by the GelCompare II v.6.5 software program (Applied Maths, 
Kortrijik, Belgium) using Dice similarity coefficient and unweighted-pair group method 
with arithmetic averages (UPGMA) with 0.5% optimization and 1.5% position tolerance.  
C. jejuni IA3902 was used as a control for identification of C. jejuni clone SA isolates.  
Lambda DNA ladder (Bio-Rad) was used as the molecular size marker.  
Multi Locus Sequence Typing 
     To further confirm the PFGE results, multilocus sequence typing (MLST) originally 
developed by Dingle et al. (42) was performed on eleven representative C. jejuni isolates 
(ten from cattle, one from starlings) from the prospective study on feedlots. Of the eleven 
isolates chosen, 4 (3 from cattle and one from starlings) had indistinguishable PFGE 
profiles from that of the positive control (C. jejuni IA3902), 4 had minor differences in 
PFGE patterns, and 3 showed totally different PFGE profiles as compared to IA3902. The 
seven housekeeping genes from these 11 C. jejuni isolates were amplified and sequenced 
using the primer sets described at the C. jejuni MLST website 
(http://pubmlst.org/campylobacter/), which was developed by Keith Jolley and Man-Suen 
Chan at the University of Oxford (43). Allelic numbers were assigned to the isolates by 
performing BLAST searches for the assembled sequences using the single-locus query 
function, whereas sequence types were assigned using the allelic profile query function in 
the MLST database. Sequences that were identical to existing alleles in the MLST 
database were assigned the corresponding allele numbers. Novel allele profiles (n = 5) 
were assigned new sequence types (STs) within the MLST database.  
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Whole genome sequence analysis 
     The putative clone SA isolates identified by PCR screening from the retrospective 
NAHMS dairy studies were subject to whole genome sequence analysis. Total DNA was 
extracted from each isolate using the Wizard Genomic DNA Purification kit (Promega) 
and then used for whole genome sequencing (WGS). The library was constructed using 
the NEXT Ultra DNA Library Prep kit (New England Biolabs) and 250 bp paired-end 
reads were obtained using an Illumina Hiseq2500 (Bionova 42 Biotech Co.). A draft 
assembly of the sequences of each genome was generated using the de novo short-read  
assembler  Velvet (44) and  Velvet  Optimiser 
(http://bioinformatics.net.au/software.velvetoptimiser.shtml). Draft genome sequences 
were aligned and then applied to phylogenetic tree construction by Parsnp in the Harvest 
package (45). The phylogenetic tree was visualized with FigTree 
(http://tree.bio.ed.ac.uk/software/figtree). MLST typing of these isolates was performed 
using the sequences of the 7 housekeeping genes according to the scheme from 
PubMLST (https://pubmlst.org/campylobacter/). 
Statistical analysis  
     A chi-square (χ2) test was used to compare the prevalence of Campylobacter before 
and after starling intervention as well as the prevalence of clone SA in different states. P 
values less than 0.05 were considered significant.  
Results  
Overall prevalence of Campylobacter in feedlot cattle. 
     In total, 2,298 (72.1%) out of 3,184 fecal samples from feedlots were positive with 
Campylobacter. Of the 2,298 Campylobacter isolates, 1,886 (82.1%) isolates were 
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determined to be C. jejuni by PCR. The overall prevalence rate of Campylobacter were 
69.2% (554/800), 71.9% (414/576), 70.0% (210/300), 78.2% (593/758) and 70.3% 
(527/750) in Iowa, Texas, Missouri, Colorado and Kansas, respectively. The 
Campylobacter prevalence rates among the states were not statistically different (p > 
0.05). Of these Campylobacter isolates in each state, 487 (87.9%), 367 (88.6%), 191 
(91.0%), 438 (73.9%) and 403 (76.5%) were identified as C. jejuni, respectively 
(Table.1), indicating that C. jejuni was the predominant Campylobacter species isolates 
from cattle feces. 
 
Table 1. Prevalence of Campylobacter jejuni and C. jejuni clone SA in feces of feedlot 
cattle and starlings in the United States 
 
      Cattle isolates              Bird isolates 
State 
% Campylobacter 
in cattle 
(No. isolates/ total 
No. samples) 
C. jejuni 
(%) 
Clone SA 
(%) 
% Campylobacter 
in birds 
(No. isolates/ total 
No. isolates) 
C. jejuni 
(%)  
Clone 
SA (%) 
Iowa 69.2 (554/800) 487 (87.9) 16 (3.3) N/A N/A N/A 
Texas 71.9 (414/576) 367 (88.6) 42 (11.4) 25.8 (23/89) 23 (100) 1 (4.3) 
Missouri 70.0 (210/300)  191 (91.0) 15 (7.9) 90.9 (10/11) 10 (100) 0 
Colorado 78.2 (593/758) 438 (73.9) 14 (3.2) 55.0 (11/20) 10 (91.0) 0 
Kansas 70.3 (527/750) 403 (76.5) 23 (5.7) 23.3 (7/30) 7 (100) 0 
Total 72.2 (2298/3184) 1886 (82.1) 110 (5.8) 34.0 (51/150) 50 (98.0) 1 (2.0) 
 
N/A: starling samples were not available – 
 
Effect of starling intervention on Campylobacter prevalence in feedlot cattle. 
     Delineation of the prevalence data by pre-/post- starling intervention program is 
shown in Table 2. The intervention program did not appear to significantly affect the 
overall prevalence of Campylobacter (p = 0.10) and C. jejuni (p = 0.29) in the feedlot 
  
 
 
cattle in this study. Before intervention, the overall prevalence of Campylobacter (69.1%; 1044/1510 samples tested) and the 
relative prevalence rates of C. jejuni (79.3%; 828/1044) were comparable to those observed post-intervention (74.9% and 
84.4%, respectively). Also, analysis of data by each state separately indicated no significant differences between pre-
intervention and post-intervention in the prevalence rates for overall Campylobacter and C. jejuni (Table. 2).  
 
Table 2. Prevalence of Campylobacter isolated from fecal samples of feedlot cattle before  
 
Prevalence of C. jejuni clone SA in feedlot cattle. 
     Initial screening of the C. jejuni isolates for putative clone SA using PCR revealed that 8.7% (164/1886) of the isolates were 
positive with the PCR. As this PCR test is not 100% specific for clone SA, PFGE was performed to confirm their identity. Of 
the 164 isolates initially identified by the PCR as putative clone SA, 110 (67.1%) had patterns that matched to the known 
subtypes of clone SA: I and II (Fig. 1a), which is in accordance with our previously published results (29). Additionally, MLST
State 
                   Pre-intervention                    Post-intervention 
No. Sample 
tested  
Positive 
samples (%)  
C. jejuni 
(%) 
Clone 
SA (%) 
No. Sample 
tested  
Positive 
samples (%) 
C. jejuni 
(%) 
Clone 
SA (%) 
Iowa 400 280 (70.0) 245 (87.5) 7 (2.9) 400 273 (68.3) 242 (88.6) 9 (3.7) 
Texas 250 170 (68.0) 144 (84.7) 12 (8.3) 326 244 (74.8) 223 (91.4) 30 (13.5) 
Missouri 150 85 (56.7) 72 (84.7) 5 (6.9) 150 125 (83.3) 119 (95.2) 10 (8.4) 
Colorado 360 274 (76.1) 202 (80.3) 6 (3.0) 398 319 (80.2) 236 (74.0) 8 (3.4) 
Kansas 350 235 (67.1) 165 (63.8) 6 (3.6) 400 292 (73.0) 238 (81.5) 17 (7.1) 
Total 1510 1044 (69.1) 828 (79.3) 36 (4.3) 1674 1253 (74.9) 1058 (84.4) 74 (7.0) 
4
5
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was performed on a subset of these isolates in both PFGE subtypes, which identified all 
of them as ST-8 genotype, which confirmed the PFGE typing result. MLST also 
performed on seven isolates with non-clone SA PFGE patterns, two of which with one 
band difference from clone SA were also identified as ST-8 genotype, while the 
remaining five isolates were identified with sequence types different from ST-8, including 
ST-2876, ST-93, ST-239, and ST-14.  
     Based on the genotyping results, a relative prevalence of 5.8% (110 out of 1886 C. 
jejuni isolates) and an absolute prevalence of 3.5% (110 out of 3184 total samples tested) 
were calculated for clone SA occurrence in the feedlot cattle surveyed in this study. The 
absolute prevalence rates of clone SA varied by state: 1.8% (14/758) in Colorado, 2.0% 
(16/800) in Iowa, 3.1% (23/750) in Kansas, 5.0% (15/300) in Missouri, and 7.3% 
(42/576) in Texas (Table.1).   The χ2 test revealed that at least one state is significantly 
different from the rest (p< 0.0001) The relative prevalence rate of clone SA also varied by 
states: Iowa 2.9% (16/554), Texas 10.1% (42/414), Missouri 7.1% (15/210), Colorado 
2.4% (14/593) and Kansas 4.4% (23/527) (p< 0.0001). However, starling intervention did 
not affect the prevalence of clone SA on the surveyed farms (Table 2). Clone SA strains 
were isolated from at least half of the feedlots surveyed in each state, in the range of 1 to 
28 isolates per feedlot (result not shown). Although PFGE was performed only on 
putative clone SA isolates identified by PCR, the non-clone SA C. jejuni isolates showed 
diverse PFGE patterns (Fig. 1), suggesting the overall genetic diversity of C. jejuni 
isolates from feedlot cattle. These findings indicate that C. jejuni clone SA is widely 
distributed and constitutes a substantial portion (~ 6%) of the total C. jejuni population in 
feedlot cattle. 
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Presence of Campylobacter including Clone SA in starlings. 
     European Starlings are commonly found on farms, serving as a potential transmission 
vehicle for Campylobacter (46). To investigate whether they may be a source of farm cattle 
infection of C. jejuni clone SA, fecal samples from European starlings present on 7 feedlots 
were tested for Campylobacter occurrence. Of note, the same feedlots were also sampled 
for cattle feces at or about the same time of starling survey. Of the 150 total starling fecal 
samples tested, 51 (34%) were positive for Campylobacter, of which 50（98%) were 
identified as C. jejuni by PCR and the remaining one isolate was of a species other than C. 
jejuni or C. coli. Initial screening using PCR identified one of the 50 C. jejuni isolates to 
be a putative clone SA (Table.1). This isolate and additional 14 randomly chosen C. jejuni 
isolates were analyzed by PFGE, which confirmed the putative clone SA isolate identified 
by PCR had a PFGE pattern indistinguishable from IA 3902 of clone SA (Fig. 1). MLST 
analysis further identified this starling isolate as ST-8, indicating it was a clone SA isolate. 
However, most (12/15) starling isolates showed PFGE patterns divergent from the cattle 
isolates and clustered distantly from the cattle isolates in the dendrogram (Fig. 1). All 
together, these results indicate that starlings carry diverse C. jejuni strains and can serve as 
a vector for transmission of Campylobacter including clone SA within and between farms.  
Prevalence of Clone SA in dairy cattle 
     A previous study reported that raw milk was a main source of foodborne illness 
outbreaks caused by C. jejuni clone SA (33), suggesting the presence of clone SA in dairy 
cattle. Thus, we performed a retrospective analysis of the collections of Campylobacter 
isolates derived from dairy cattle by NAHMS.  In 2002, 2007 and 2014, NAHMS 
conducted national surveillance studies on Campylobacter prevalence in dairy cattle (17, 
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Fig. 1. Dendrogram showing the PFGE patterns (KpnI) of C. jejuni isolates from feces of 
feedlot cattle and starlings. The clone SA strains are represented by two closely 
associated PFGE patterns (I and II), as was the case in sheep clone SA isolates (29). 
IA3902 is a known isolate of clone SA and is used as a reference. The isolates’ names are 
listed on the right of the dendrogram.  “   ”indicates starling isolates. TX: Texas; CO: 
Colorado; MO: Missouri; IA: Iowa; and KS: Kansas. FC indicated feedlot cattle, while 
ST depicts starling. The numbers in the names of the isolates are arbitrary numbers 
assigned to feedlots and samples. 
34). In total, 205, 627 and 576 C. jejuni isolates collected in 2002, 2007, and 2014, 
respectively, were available for clone SA screening.  Of these C. jejuni collections, 11.2% 
(23/205), 10.5% (66/627) and 6.8% (39/576) were initially identified as putative clone SA 
by PCR (n= 128 total), respectively.  All but three (one from Dairy 2007 and two from 
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Dairy 2014) of the putative clone SA isolates were subjected to whole genome sequencing 
analysis. Overall, 16 STs were identified among the genome-sequenced isolates (Table S1). 
Of the 125 isolates sequenced, 102 (81.6%) were confirmed as clone SA, which gave a 
relative prevalence of 7.2% (102/1408) for clone SA among the C. jejuni isolates from the 
U.S. dairy cattle. These clone SA isolates included 21 (10.2%) from Dairy 2002, 55 (8.8%) 
from Dairy 2007, and 26 (3.2%) from Dairy 2014 studies (Table 3). The declining trend 
from 2002 to 2014 in the prevalence of clone SA is statistically significant (p < 0.05).  Of 
those non-clone SA isolates that were PCR positive and whole genome sequenced, fifteen 
STs were identified (Table S1), five of which were novel sequence types (i.e., they have 
not been reported previously). Of the fifteen STs, eleven STs were represented by one 
isolate each, two STs represented by two isolates, one ST represented by five isolates, and 
one ST by three isolates (Table S1).  
      As carrying tetracycline resistant gene tet(O) is one of the  key features of clone SA 
isolates from sheep (18), its presence was investigated in the dairy clone SA isolates. Result 
showed that 81 (79.4%) of the dairy clone SA isolates contained the tet(O) gene either in 
the chromosome (n = 68) or on plasmid pTet (n = 13), including 13 (61.9%) isolates from 
Dairy 2002, 51 (92.7%) isolates from Dairy 2007 and 17 (65.4%) isolates from Dairy 2014. 
In contrast, of the 23 non-clone SA isolates with whole genome sequenced, 9 isolates 
harbored a tet(O) in the pTet plasmid, but none of them had tet(O) in the chromosome. The 
pVir plasmid was also found in the NAHMS Dairy 2002 (n = 2), 2007 (n = 1) and 2014 (n 
= 2) isolates (Table. 3). 
      Previously we have determined the whole genome sequences of clone SA isolates 
derived from sheep abortion (47). To investigate the genomic relationship between the  
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Table. 3. Occurrence and characteristics of C. jejuni clone SA isolates in dairy cows  
 
Dairy 
Study* 
No. C. jejuni  
tested 
No. (%) clone SA by:  pVir 
presence 
tet (O) location 
PCR  WGS  chromosome pTet 
2002 205 23 (11.2) 21 (10.2) 2 13 3 
2007 627 66 (10.5)   55 (8.8) 1 40 9 
2014 576 39 (6.8)   26 (4.5) 2 15 1 
Total 1408 128 (9.1) 102 (7.2) 5 68 13 
*NAHMS national surveillance studies 
 
clinically abortifacient isolates from sheep and the clone SA isolates from dairy cattle 
feces, maximum-likelihood phylogenetic trees were constructed based on pangenome 
(Fig. 2a) and core genome (Fig. 2b). The trees were constructed with 170 clone SA 
isolates, including 72 isolates from sheep abortion collected previously (47) and 98 dairy 
isolates sequenced in this study (the genomic sequences of 3 dairy isolates were excluded 
due to poor quality). The 72 ovine isolates represented historical and contemporary 
isolates of clone SA in the United States over the last two decades, while the 98 bovine 
isolates were selected from the NAHMS studies (2002 - 2014). In both trees, clone SA 
isolates from sheep and cattle were intermixed and formed clusters irrespective of their 
host species, indicating that clone SA isolates were not host specific. In addition, 
although these dairy ST-8 isolates came from different time across 12 years, we didn’t 
observe any specific evolution patterns from the genomic data, suggesting the genome of 
clone SA was fairly stable. 
Discussion 
    Results from this study revealed high prevalence (72.2%) of Campylobacter spp. in 
feedlot cattle and the distribution of C. jejuni clone SA in both feedlot cattle and dairy 
cattle in the U.S.(10, 17, 26, 27). The identification of C. jejuni as the predominant 
51 
 
 
 
 
     Fig. 2. Maximum-likelihood phylogenetic tree constructed with the pangenome (a) 
and the core genome (b) differences among 170 C. jejuni clone SA isolates from sheep 
and cattle. The clone SA strains are intermixed between sheep and cattle and among the 
isolation years (2002, 2007, and 2014). The isolates are color-coded based on their source 
hosts and isolation years: red for sheep, blue for NAHMS Dairy 2002, green for NAHMS 
Dairy 2007, and black for NAHMS dairy cattle 2014. 
 
Campylobacter species in cattle is consistent with previous findings reported by others 
(17, 26).  Considering that genetically diverse C. jejuni strains are present in cattle (32), 
the prevalence of clone SA (5.8% in feedlot cattle and 7.2% in dairy cattle) is relatively 
high, suggesting that clone SA is well adapted in cattle, similar to the situation in sheep 
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(33). Additionally, we found that European starlings on cattle farms carry C. jejuni 
including clone SA and may serve as a vehicle for the transmission of Campylobacter on 
farms. Furthermore whole genome sequence analysis of the clone SA isolates collected 
from dairy cattle during 2002-2014 revealed high genomic stability of the isolates. These 
findings provide new insights into the epidemiology of C. jejuni clone SA in both beef 
and dairy cattle. To our knowledge, this is the first study that documents the distribution 
of C. jejuni clone SA in beef and dairy cattle, and the work has closed a major knowledge 
gap in understanding the ecology of this zoonotic pathogen in animal reservoirs. 
     In this study, preliminary identification of clone SA was done with a rapid PCR 
method that targets CJSA_1356, which is one of the variable genes in the capsule locus 
and is quite specific for clone SA isolates. A previous work has shown the utility of this 
PCR method for initial screening for clone SA isolates (41). However, this method is not 
100% specific for clone SA, which requires further confirmation of the putative clone SA 
isolates by other methods. For the prospective study on feedlots, we used PFGE and 
MLST to confirm the identity of clone SA. In the absence of whole genome sequences, 
PFGE and MLST are considered the gold standards for establishing clonality in 
Campylobacter isolates (33, 48). For the retrospective analysis of the dairy isolates from 
NAHMS studies, whole genome sequencing was used to confirm the identity of the clone 
SA isolates initially identified by PCR. The use of multiple approaches ensured the 
efficiency and accuracy of detecting clone SA from a large number of samples.  
     An interesting finding is that the prevalence rate of clone SA varied significantly in 
feedlots of different states, highest (7.3%) in Texas and lowest (2.4%) in Colorado. Even 
within a single state, the prevalence varied from farm to farm. For example, the highest 
53 
 
 
 
prevalence of clone SA was detected with #4 feedlot in Texas, where 22 of 47 isolates 
tested were identified as clone SA, including the clone SA isolate from starling.  The 
exact reasons for the variable prevalence in different feedlots and states are unknown, but 
it is possible that the variations are related to differences in management practices that 
influence transmission and persistence of clone SA in cattle feedlots.   
     NAHMS examined Campylobacter prevalence in dairy cows by analyzing individual 
fecal samples in three separate studies: Dairy 2002 (17), Dairy 2007 (34), and Dairy 
2014. In the Dairy 2002 study, a total of 1,435 fecal samples from 96 dairy operations in 
21 states were collected, and the overall prevalence of Campylobacter was found to be 
51.2% (17). In the Dairy 2007 study, 1,885 fecal samples were collected from 121 dairy 
operations in 17 states, and 33.7% (635/1885) of the samples were Campylobacter 
positive (34). By taking advantage of NAHMS' collections of Campylobacter isolates, we 
were able to determine the prevalence of clone SA in dairy cattle on a national scale. The 
availability of isolates from studies conducted in three different years (2002, 2007, and 
2014) allowed us to examine the dynamic changes in clone SA prevalence over the years. 
Interestingly, the prevalence of clone SA in 2002 and 2007 comparable: 10.2% and 8.8%, 
respectively. However, in 2014, the prevalence decreased to 4.5%, which is significantly 
different from the previous two studies. What is responsible for the overall declining 
trend of clone SA in dairy cattle is interesting and remains to be determined in future 
studies.  
     It was found in this study that 34% of starling fecal samples were Campylobacter 
positive, with C. jejuni identified as the predominant Campylobacter species. This 
prevalence rate is within the range of 11.1% - 50.4% previously reported in the United 
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States and outside the United States (36, 46, 49, 50). PCR screening and molecular typing 
identified one clone SA isolate in the starling samples. Additionally, PFGE analysis of 
selected starling isolates revealed genetically diverse strains (Fig. 1), consistent with 
previous findings in starlings (50, 51). Despite the genetic diversity, two isolates 
(including a clone SA isolate) showed indistinguishable PFGE patterns with the cattle 
isolates (Fig. 1), suggesting that starlings play a role in spreading Campylobacter on 
cattle farms. It should be pointed out that PFGE analysis of the cattle isolates was biased 
toward putative clone SA isolates and did not represent the entire genetic profiles of the 
cattle isolates. Thus, the matching between the cattle and starling isolates might be even 
higher if more cattle isolates (non-clone SA) were analyzed by PFGE.  Regardless, 
results from this study demonstrated frequent isolation of Campylobacter from European 
starlings on cattle farms and suggest possible two-way transmission of Campylobacter 
between the two animal species. Interestingly, starling intervention on farms did not 
affect the overall prevalence of Campylobacter (Table 2). This may be due to the fact that 
multiple factors contribute to the transmission of Campylobacter on cattle farms and 
control of a single factor has limited impact on its prevalence.  
     The advance of next-generation sequencing technologies has made it possible to 
perform high-resolution molecular typing of bacterial isolates. We conducted whole 
genome analysis of the putative clone SA isolates from NAHMS dairy studies, not only 
for identification of clone SA, but also for understanding evolution of clone SA over the 
last 12 (2002-2014) years. The whole genome sequence analysis confirmed that 102 of 
the 128 putative clone SA isolates identified by PCR were true clone SA isolates. The 
genomic data were further used for maximum-likelihood phylogenetic tree construction, 
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which revealed that the clone SA isolates derived from 2002-2014 are genetically stable 
and a clear pattern of evolution was not detected as indicted by lack of clustering of the 
isolates by isolation years (Fig 2). Inclusion of sheep clone SA isolates (47) in the 
phylogenetic analysis also revealed that the sheep and cattle isolates are mixed in 
clustering (Fig. 2), suggesting that the genomics sequences of clone SA isolates are not 
associated with host species and the possibility of inter-species (cattle and sheep) 
transmission of clone SA. These genomic features further support the notion that C. 
jejuni clone SA is well adapted in the ruminant reservoirs.  
     Tetracycline resistance is an important feature of C. jejuni clone SA isolated from 
sheep  and acquisition of this resistance trait is like due to antibiotic selection pressure as 
tetracyclines are frequently used for control of sheep abortion on farms in the U.S. (33, 
52).  The tet (O) is the only tetracycline resistance determinant identified in 
Campylobacter so far. The tet(O) gene is normally carried by plasmids, but in clone SA it 
is predominantly located in chromosome (33). In this study, we found that 79.4% (Table. 
3) of the dairy clone SA isolates carried the tet(O) gene,  and in most of the isolates 
(68/81) it was located on chromosome. However, the tet(O) gene in the non-clone SA 
isolates was all carried by a plasmid.  These results are consistent with our previous 
findings with the sheep Campylobacter isolates (52) and further indicate the advantage of 
C. jejuni clone SA in dealing with the selection pressure from tetracycline antibiotics. The 
pVir plasmid was also identified in a small number (5/102) of clone SA isolates in this 
study. This plasmid is not required for abortion induction by clone SA (53) and is also 
infrequently present in sheep clone SA isolates (47). Thus, pTet is not a unique to clone 
SA and its in vivo function is still unknown. 
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     In summary, this study revealed detailed molecular and epidemiological features of C. 
jejuni clone SA in beef and dairy cattle as well as in European starlings present on cattle 
farms. These findings underscore the importance of cattle and wild birds in the overall 
ecology of C.jejuni clone SA in animal reservoirs and provide critically needed information 
for development of intervention strategies. Considering the significance of C. jejuni clone 
SA in ruminant health and food safety, reducing its prevalence on cattle farms will benefit 
both animal health and public health.   
Acknowledgement 
     We thank Nada Pavlovic for technical assistance.  
Funding  
     This project was supported by Agriculture and Food Research Initiative Competitive 
Grant no. 2012-67005-19614 and nol 2013-67015-20368 from the USDA National  
Institute of Food and Agriculture. 
Transparency declarations 
     None to declare. 
 
References: 
 
1. Fitzgerald C. 2015. Campylobacter. Clin Lab Med 35:289-298. 
 
2. Chowdhury MN. 1984. Campylobacter jejuni enteritis; a review. Trop Geogr 
Med 36:215-222. 
 
3. CDC. 2016. Infection with Pathogens Transmitted Commonly Through Food and 
the Effect of Increasing Use of Culture-Independent Diagnostic Tests on 
Surveillance —Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 
2012–2015. Morbidity and Mortality Weekly Report, April 15, 2016. 
 
57 
 
 
 
4. Elvers KT, Morris VK, Newell DG, Allen VM. 2011. Molecular tracking, 
through processing, of Campylobacter strains colonizing broiler flocks. Appl 
Environ Microbiol 77:5722-5729. 
 
5. Berrang ME, Bailey JS, Altekruse SF, Patel B, Shaw WK, Jr., Meinersmann 
RJ, Fedorka-Cray PJ. 2007. Prevalence and numbers of Campylobacter on 
broiler carcasses collected at rehang and postchill in 20 U.S. processing plants. J 
Food Prot 70:1556-1560. 
 
6. Hannon SJ, Taboada EN, Russell ML, Allan B, Waldner C, Wilson HL, 
Potter A, Babiuk L, Townsend HG. 2009. Genomics-based molecular 
epidemiology of Campylobacter jejuni isolates from feedlot cattle and from 
people in Alberta, Canada. J Clin Microbiol 47:410-420. 
 
7. Mullner P, Shadbolt T, Collins-Emerson JM, Midwinter AC, Spencer SE, 
Marshall J, Carter PE, Campbell DM, Wilson DJ, Hathaway S, Pirie R, 
French NP. 2010. Molecular and spatial epidemiology of human 
campylobacteriosis: source association and genotype-related risk factors. 
Epidemiol Infect 138:1372-1383. 
 
8. Clark CG, Price L, Ahmed R, Woodward DL, Melito PL, Rodgers FG, 
Jamieson F, Ciebin B, Li A, Ellis A. 2003. Characterization of waterborne 
outbreak-associated Campylobacter jejuni, Walkerton, Ontario. Emerg Infect Dis 
9:1232-1241. 
 
9. Centers for Disease C, Prevention. 2009. Campylobacter jejuni infection 
associated with unpasteurized milk and cheese--Kansas, 2007. MMWR Morb 
Mortal Wkly Rep 57:1377-1379. 
 
10. Stanley K, Jones K. 2003. Cattle and sheep farms as reservoirs of 
Campylobacter. J Appl Microbiol 94 Suppl:104S-113S. 
 
11. Wilson DJ, Gabriel E, Leatherbarrow AJ, Cheesbrough J, Gee S, Bolton E, 
Fox A, Fearnhead P, Hart CA, Diggle PJ. 2008. Tracing the source of 
campylobacteriosis. PLoS Genet 4:e1000203. 
 
12. Heuvelink AE, van Heerwaarden C, Zwartkruis-Nahuis A, Tilburg JJ, Bos 
MH, Heilmann FG, Hofhuis A, Hoekstra T, de Boer E. 2009. Two outbreaks 
of campylobacteriosis associated with the consumption of raw cows' milk. Int J 
Food Microbiol 134:70-74. 
 
13. Lejeune JT, Rajala-Schultz PJ. 2009. Food safety: unpasteurized milk: a 
continued public health threat. Clin Infect Dis 48:93-100. 
 
58 
 
 
 
14. Newkirk R, Hedberg C, Bender J. 2011. Establishing a milkborne disease 
outbreak profile: potential food defense implications. Foodborne Pathog Dis 
8:433-437. 
 
15. Jacobs-Reitsma W LU, Wagenaar J. 2008. Campylobacter in the food supply, p 
627–644. In Nachamkin I, Szymanski CM, and Blaser MJ (ed), Campylobacter, 
3rd ed ASM Press, Washington, DC. 
 
16. Horrocks SM, Anderson RC, Nisbet DJ, Ricke SC. 2009. Incidence and 
ecology of Campylobacter jejuni and coli in animals. Anaerobe 15:18-25. 
 
17. Englen MD, Hill AE, Dargatz DA, Ladely SR, Fedorka-Cray PJ. 2007. 
Prevalence and antimicrobial resistance of Campylobacter in US dairy cattle. J 
Appl Microbiol 102:1570-1577. 
 
18. Sato K, Bartlett PC, Kaneene JB, Downes FP. 2004. Comparison of prevalence 
and antimicrobial susceptibilities of Campylobacter spp. isolates from organic and 
conventional dairy herds in Wisconsin. Appl Environ Microbiol 70:1442-1447. 
 
19. Oporto B, Esteban JI, Aduriz G, Juste RA, Hurtado A. 2007. Prevalence and 
strain diversity of thermophilic campylobacters in cattle, sheep and swine farms. J 
Appl Microbiol 103:977-984. 
 
20. Chatre P, Haenni M, Meunier D, Botrel MA, Calavas D, Madec JY. 2010. 
Prevalence and antimicrobial resistance of Campylobacter jejuni and 
Campylobacter coli isolated from cattle between 2002 and 2006 in France. J Food 
Prot 73:825-831. 
 
21. Krueger NA, Anderson RC, Krueger WK, Horne WJ, Wesley IV, Callaway 
TR, Edrington TS, Carstens GE, Harvey RB, Nisbet DJ. 2008. Prevalence and 
concentration of Campylobacter in rumen contents and feces in pasture and 
feedlot-fed cattle. Foodborne Pathog Dis 5:571-577. 
 
22. Halbert LW, Kaneene JB, Ruegg PL, Warnick LD, Wells SJ, Mansfield LS, 
Fossler CP, Campbell AM, Geiger-Zwald AM. 2006. Evaluation of 
antimicrobial susceptibility patterns in Campylobacter spp isolated from dairy 
cattle and farms managed organically and conventionally in the midwestern and 
northeastern United States. J Am Vet Med Assoc 228:1074-1081. 
 
23. Bae W, Kaya KN, Hancock DD, Call DR, Park YH, Besser TE. 2005. 
Prevalence and antimicrobial resistance of thermophilic Campylobacter spp. from 
cattle farms in Washington State. Appl Environ Microbiol 71:169-174. 
 
24. Wesley IV, Wells SJ, Harmon KM, Green A, Schroeder-Tucker L, Glover M, 
Siddique I. 2000. Fecal shedding of Campylobacter and Arcobacter spp. in dairy 
cattle. Appl Environ Microbiol 66:1994-2000. 
59 
 
 
 
 
25. Sanad YM, Kassem, II, Abley M, Gebreyes W, LeJeune JT, Rajashekara G. 
2011. Genotypic and phenotypic properties of cattle-associated Campylobacter 
and their implications to public health in the USA. PLoS One 6:e25778. 
 
26. Englen MD, Fedorka-Cray PJ, Ladely SR, Dargatz DA. 2005. Antimicrobial 
resistance patterns of Campylobacter from feedlot cattle*. J Appl Microbiol 
99:285-291. 
 
27. Besser TE, Lejeune JT, Rice DH, Berg J, Stilborn RP, Kaya K, Bae W, 
Hancock DD. 2005. Increasing prevalence of Campylobacter jejuni in feedlot 
cattle through the feeding period. Appl Environ Microbiol 71:5752-5758. 
 
28. Smith JL. 2002. Campylobacter jejuni infection during pregnancy: long-term 
consequences of associated bacteremia, Guillain-Barre syndrome, and reactive 
arthritist. J Food Prot 65:696-708. 
 
29. Sahin O, Plummer PJ, Jordan DM, Sulaj K, Pereira S, Robbe-Austerman S, 
Wang L, Yaeger MJ, Hoffman LJ, Zhang Q. 2008. Emergence of a 
tetracycline-resistant Campylobacter jejuni clone associated with outbreaks of 
ovine abortion in the United States. J Clin Microbiol 46:1663-1671. 
 
30. Delong WJ, Jaworski MD, Ward AC. 1996. Antigenic and restriction enzyme 
analysis of Campylobacter spp associated with abortion in sheep. Am J Vet Res 
57:163-167. 
 
31. Kirkbride CA. 1993. Diagnoses in 1,784 ovine abortions and stillbirths. J Vet 
Diagn Invest 5:398-402. 
 
32. Wu Z, Sippy R, Sahin O, Plummer P, Vidal A, Newell D, Zhang Q. 2014. 
Genetic diversity and antimicrobial susceptibility of Campylobacter jejuni isolates 
associated with sheep abortion in the United States and Great Britain. J Clin 
Microbiol 52:1853-1861. 
 
33. Sahin O, Fitzgerald C, Stroika S, Zhao S, Sippy RJ, Kwan P, Plummer PJ, 
Han J, Yaeger MJ, Zhang Q. 2012. Molecular evidence for zoonotic 
transmission of an emergent, highly pathogenic Campylobacter jejuni clone in the 
United States. J Clin Microbiol 50:680-687. 
 
34. USDA. 2011. Salmonella, Listeria, and Camplobacter on U.S. Dairy Operation, 
1996-2007. USDA-APHIS-VS, CEAH Fort Collins, CO #5780311. 
 
35. Carlson JC, Engeman RM, Hyatt DR, Gilliland RL, DeLiberto TJ, Clark L, 
Bodenchuk MJ, Linz GM. 2011. Efficacy of European starling control to reduce 
Salmonella enterica contamination in a concentrated animal feeding operation in 
the Texas panhandle. BMC Vet Res 7:9. 
60 
 
 
 
 
36. Sanad YM, Closs G, Jr., Kumar A, LeJeune JT, Rajashekara G. 2013. 
Molecular epidemiology and public health relevance of Campylobacter isolated 
from dairy cattle and European starlings in Ohio, USA. Foodborne Pathog Dis 
10:229-236. 
 
37. USDA. 2016. Dairy Cattle Management Practices in the United States, 2014. 
USDA–APHIS–VS–CEAH–NAHMS, Fort Collins, CO 80526–8117. 
 
38. Olah PA, Doetkott C, Fakhr MK, Logue CM. 2006. Prevalence of the 
Campylobacter multi-drug efflux pump (CmeABC) in Campylobacter spp. 
Isolated from freshly processed Turkeys. Food Microbiol 23:453-460. 
 
39. Linton D, Lawson AJ, Owen RJ, Stanley J. 1997. PCR detection, identification 
to species level, and fingerprinting of Campylobacter jejuni and Campylobacter 
coli direct from diarrheic samples. J Clin Microbiol 35:2568-2572. 
 
40. Linton D, Owen RJ, Stanley J. 1996. Rapid identification by PCR of the genus 
Campylobacter and of five Campylobacter species enteropathogenic for man and 
animals. Res Microbiol 147:707-718. 
 
41. Luo Y, Sahin O, Dai L, Sippy R, Wu Z, Zhang Q. 2012. Development of a 
loop-mediated isothermal amplification assay for rapid, sensitive and specific 
detection of a Campylobacter jejuni clone. J Vet Med Sci 74:591-596. 
 
42. Dingle KE, Colles FM, Wareing DR, Ure R, Fox AJ, Bolton FE, Bootsma HJ, 
Willems RJ, Urwin R, Maiden MC. 2001. Multilocus sequence typing system 
for Campylobacter jejuni. J Clin Microbiol 39:14-23. 
 
43. Jolley KA, Chan MS, Maiden MC. 2004. mlstdbNet - distributed multi-locus 
sequence typing (MLST) databases. BMC Bioinformatics 5:86. 
 
44. Zerbino DR, Birney E. 2008. Velvet: algorithms for de novo short read assembly 
using de Bruijn graphs. Genome Res 18:821-829. 
 
45. Treangen TJ, Ondov BD, Koren S, Phillippy AM. 2014. The Harvest suite for 
rapid core-genome alignment and visualization of thousands of intraspecific 
microbial genomes. Genome Biol 15:524. 
 
46. Colles FM, McCarthy ND, Howe JC, Devereux CL, Gosler AG, Maiden MC. 
2009. Dynamics of Campylobacter colonization of a natural host, Sturnus vulgaris 
(European starling). Environ Microbiol 11:258-267. 
 
47. Wu Z, Periaswamy B, Sahin O, Yaeger M, Plummer P, Zhai W, Shen Z, Dai 
L, Chen SL, Zhang Q. 2016. Point mutations in the major outer membrane 
61 
 
 
 
protein drive hypervirulence of a rapidly expanding clone of Campylobacter 
jejuni. Proc Natl Acad Sci U S A 113:10690-10695. 
 
48. Lucarelli C, Dionisi AM, Trezzi L, Farina C, Passera M, Karki T, D'Ancona 
F, Luzzi I. 2016. Molecular and Epidemiological Analysis of a Campylobacter 
jejuni Outbreak in Northern Italy in November 2013. Foodborne Pathog Dis 
13:490-494. 
 
49. Waldenstrom J, Broman T, Carlsson I, Hasselquist D, Achterberg RP, 
Wagenaar JA, Olsen B. 2002. Prevalence of Campylobacter jejuni, 
Campylobacter lari, and Campylobacter coli in different ecological guilds and 
taxa of migrating birds. Appl Environ Microbiol 68:5911-5917. 
 
50. Sippy R, Sandoval-Green CM, Sahin O, Plummer P, Fairbanks WS, Zhang 
Q, Blanchong JA. 2012. Occurrence and molecular analysis of Campylobacter in 
wildlife on livestock farms. Vet Microbiol 157:369-375. 
 
51. French NP, Midwinter A, Holland B, Collins-Emerson J, Pattison R, Colles 
F, Carter P. 2009. Molecular epidemiology of Campylobacter jejuni isolates 
from wild-bird fecal material in children's playgrounds. Appl Environ Microbiol 
75:779-783. 
 
52. Wu Z, Sahin O, Shen Z, Liu P, Miller WG, Zhang Q. 2013. Multi-omics 
approaches to deciphering a hypervirulent strain of Campylobacter jejuni. 
Genome Biol Evol 5:2217-2230. 
 
53. Shen Z, Patil RD, Sahin O, Wu Z, Pu XY, Dai L, Plummer PJ, Yaeger MJ, 
Zhang Q. 2016. Identification and functional analysis of two toxin-antitoxin 
systems in Campylobacter jejuni. Mol Microbiol 101:909-923. 
 
  
 
 
 
 
 
 
 
62 
 
 
 
CHAPTER 4. RISING FLUOROQUINOLONE RESISTANCE IN 
CAMPYLOBACTER ISOLATED FROM FEEDLOT CATTLE IN THE UNITED 
STATES. 
A paper published in Scientific Reports 
Yizhi Tang1, Orhan Sahin1,2*, Nada Pavlovic1,  Jeff LeJeune3, James Carlson4, Zuowei 
Wu1, Lei Dai1 and Qijing Zhang1* 
1Department of Veterinary Microbiology and Preventive Medicine, and 2Department of 
Veterinary Diagnostic and Production Animal Medicine, Ames, IA, USA; 3Food Animal 
Health Research Program, Ohio State University, Wooster, OH; 4National Wildlife 
Research Center, USDA APHIS, Fort Collins, CO. 
 
*Send correspondence to osahin@iastate.edu, or zhang123@iastate.edu  
 
 
 
 
 
 
 
63 
 
 
 
Abstract 
     Antibiotic resistance, particularly to fluoroquinolones and macrolides, in the major 
foodborne pathogen Campylobacter is considered a serious threat to public health. 
Although ruminant animals serve as a significant reservoir for Campylobacter, limited 
information is available on antibiotic-resistant Campylobacter of bovine origin. Here, we 
analyzed the antimicrobial susceptibilities of 320 C. jejuni and 115 C. coli isolates 
obtained from feedlot cattle farms in multiple states in the U.S.  The results indicate that 
fluoroquinolone resistance reached to 35.4% in C. jejuni and 74.4% in C. coli, which are 
significantly higher than those previously reported in the U.S. While all fluoroquinolone 
resistant (FQR) C. coli isolates examined in this study harbored the single Thr-86-Ile 
mutation in GyrA, FQR C. jejuni isolates had other mutations in GyrA in addition to the 
Thr-86-Ile change. Notably, most of the analyzed FQR C. coli isolates had similar PFGE 
(pulsed field gel electrophoresis) patterns and the same MLST (multilocus sequence 
typing) sequence type (ST-1068) regardless of their geographic sources and time of 
isolation, while the analyzed C. jejuni isolates were genetically diverse, suggesting that 
clonal expansion is involved in dissemination of FQR C. coli but not C. jejuni. These 
findings reveal the rising prevalence of FQR Campylobacter in the U.S. and provide 
novel information on the epidemiology of antibiotic-resistant Campylobacter in the 
ruminant reservoir. 
 
Introduction 
     Campylobacter is a leading cause of bacterial foodborne gastroenteritis worldwide and 
is a major public health problem.1,2 Although the majority of Campylobacter infections 
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are self-limited and do not require antimicrobial treatment, antibiotics are indicated for 
severe and chronic conditions.3 Clinical treatment of campylobacteriosis requires the use 
of fluoroquinolone (FQ) or macrolide antibiotics. However, antibiotic-resistant 
Campylobacter is becoming increasingly prevalent. Due to the rising resistance, 
especially to FQ, the Centers for Disease Control and Prevention (CDC) has recently 
identified drug-resistant Campylobacter as a serious antibiotic resistance threat in the 
United States.4 The CDC reported that almost 25% of human Campylobacter isolates 
were resistant to ciprofloxacin in the USA.4 Development and transmission of antibiotic 
resistant Campylobacter is complicated by the fact that Campylobacter is a zoonotic 
pathogen and is exposed to antibiotics used in both animal production and human 
medicine.  
    Contaminated poultry meat is frequently recognized as the major source for human 
infections.5 However, ruminants also play a significant role in epidemiology of human 
Campylobacter infections and are increasingly reported as the implicated source.6-9 
Ruminant Campylobacter contributes to human disease via multiple transmission routes 
including direct contact (e.g. petting zoo and occupational exposure), consumption of 
unpasteurized milk (and associated dairy products), and environmental contamination 
(e.g., water and produce).10-12 Molecular typing methods, such as multilocus sequence 
typing (MLST) and pulsed field gel electrophoresis (PFGE), revealed that certain 
genotypes of C. jejuni from ruminants are indistinguishable from human isolates,12-14 
linking ruminant Campylobacter to human diseases. Raw milk is a well-recognized 
transmission route as a number of raw milk associated outbreaks of campylobacteriosis 
have been documented.15-18 Ruminant Campylobacter may also contaminate water 
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supplies via agricultural runoff. A waterborne outbreak associated with Campylobacter 
was reported to be the result of contamination of the town’s water supply with 
Campylobacter originating from a cattle farm in the vicinity.11 Thus, control of 
Campylobacter in ruminants will have a direct impact on food safety and human health.  
     Despite the importance of ruminant Campylobacter in foodborne disease, few studies 
have been conducted to understand antibiotic-resistant Campylobacter from cattle. Earlier 
reports from the U.S. (including the Feedlot 1999 and Dairy 2002 NAHMS studies) and 
Canada indicated very low levels of FQ resistance (less than 5%) in Campylobacter 
isolates from cattle.19-22 Bae et al.23 also reported a low level (ca. 5%) of resistance to 
ciprofloxacin in C. jejuni from different cattle production types in Western U.S., although 
C. coli isolates from the same study had much higher (ca. 45%) resistance rate to this 
drug during 2002-2003. Similarly, a study on Campylobacter from dairy cattle in the 
Midwest U.S. during mid-2000s indicated that less than 1% of isolates were resistant to 
ciprofloxacin.24 However, a slaughterhouse survey25 conducted during late 2008 in the 
U.S. found that high percentage of both C. jejuni and C. coli (27.3% and 49.2%, 
respectively) from different types of cattle types (including both feedlot cattle and adult 
cows and bulls) were resistant to ciprofloxacin. 
     These observations point to a possible rising trend of FQ-resistance in the U.S. and 
highlight the need for conducting surveillance studies on a national scale to assess 
antibiotic resistance in ruminant Campylobacter.  Although the National Antimicrobial 
Resistance Monitoring System (NARMS) operated by USDA monitors the occurrence of 
antimicrobial resistance in Campylobacter isolates from food animals at slaughter, the 
sampling and testing strategy does not include cattle and is limited to chicken carcass 
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rinsates (http://www.ars.usda.gov/Main/docs.htm?docid=6750&page=2).  To understand 
the ecology and facilitate control of antimicrobial resistant Campylobacter in the 
ruminant reservoir, we determined in this study the antimicrobial susceptibility of 
Campylobacter isolates derived from feedlot cattle operations in geographically diverse 
regions in the U.S.  
Results 
Prevalence of Campylobacter in feedlot cattle  
     The overall prevalence rate of Campylobacter in the feedlot cattle feces was 72.2% 
(2298/3184), and ranged between 69.2 – 78.2% among the different states from which the 
samples were derived. Of the Campylobacter isolates, 82.1% (1886/2298) were identified 
as C. jejuni, and 15.0% (344/2298) were determined to be C. coli by PCR (Fig. S1). The 
remaining 68 isolates (2.9%) were of different Campylobacter spp. than C. jejuni and C. 
coli and were not characterized further to species level (Table 1).  
Antimicrobial susceptibility of the C. jejuni and C. coli isolates from feedlot cattle 
     Of the 320 representative cattle C. jejuni isolates selected across the 35 feedlots tested 
in this study, 281 (88.1%) were found to be resistant to tetracycline, 114 (35.6%) were 
resistant to ciprofloxacin, and 110 (34.3%) were resistant to nalidixic acid. Resistance to 
azithromycin, clindamycin, erythromycin, florfenicol, gentamicin and telithromycin was 
low (one isolate for each) (Table 2). Among the 115 representative cattle C. coli isolates 
tested, 86 (74.8%) were found to be resistant to tetracycline, 89 (77.4%) were resistant to 
ciprofloxacin, 95 (82.6%) were resistant to nalidixic acid, and 5 (4.3%) were resistant to 
florfenicol and clindamycin. None of the C. coli isolates were resistant to azithromycin, 
erythormycin, gentamicin or telithromycin (Table 2). The ciprofloxacin resistance in 
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Table 1. Campylobacter species isolated from fecal samples of feedlot cattle from five 
states in the U.S. 
State Feedlot herds Cattle samples Positive cattle (%) C. jejuni (%) C. coli (%) 
Iowa 8 800 554 (69.2) 487 (87.9) 56 (10.1) 
Texas 8 576 414 (71.9) 367 (88.6) 35 (8.5) 
Missouri 3 300 210 (70.0) 191 (91.0) 16 (7.6) 
Colorado 8 758 593 (78.2) 438 (81.5) 124 (20.9) 
Kansas 8 750 527 (70.3) 403 (76.5) 113 (21.4) 
Total 35 3184 2298(72.2) 1886 (82.1) 344 (15.0) 
 
C. coli (77.4%) was significantly (P < 0.05) higher than in C. jejuni (35.6%), as was the 
resistance rate for nalidixic acid (82.6% vs. 34.3%), whereas resistance to tetracycline 
was comparable (74.8% vs. 88.1%) between C. coli and C. jejuni (P > 0.05), respectively 
(Table 2). The resistance rates of either C. jejuni or C. coli isolates for tetracycline, 
ciprofloxacin and nalidixic acid did not vary substantially among different states (Data 
not shown). These results indicated an overall high rate of FQ resistance in feedlot cattle 
Campylobacter isolates, especially in C. coli. 
     Multiple drug resistance in C. jejuni and C. coli from cattle was observed frequently. 
Of the 320 C. jejuni isolates tested, 114 (35.6%) were resistant to two or more 
antimicrobial agents, 100 (31.2%) were resistant to three or more antibiotics, 3 were 
resistant to four or more agents, 2 were resistant to five or more drugs, and 1 was resistant 
to seven antibiotics including azithromycin, ciprofloxacin, erythromycin, gentamicin, 
tetracycline, nalidixic acid and telithromycin (Table 3). None of the C. jejuni isolates  
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   Table 2. Prevalence of antimicrobial resistance in Campylobacter jejuni (n=320) and C. 
coli (n=115) from feedlot cattle. 
Antibiotics 
Range tested 
(μg/ml) 
Resistance breakpoint  
(μg/ml) 
No. (%) of resistance in 
cattle 
C. jejuni C. coli 
Azithromycin 0.015-64 ≥8 1 (0.3) 0 
Ciprofloxacin 0.015-64 ≥4 114 (35.6) 89 (77.4)* 
Clindamycin 0.03-16 ≥8 1 (0.3) 5 (4.3) 
Erythromycin 0.03-64 ≥32 1 (0.3) 0 
Florfenicol 0.03-64 ≥16 1 (0.3) 5 (4.3) 
Gentamicin 0.12-32 ≥8 1 (0.3) 0 
Nalidixic acid 4.0-64 ≥32 110 (34.3) 95 (82.6)* 
Telithromycin 0.015-8 ≥16 1 (0.3) 0 
Tetracycline 0.06-64 ≥16 281 (88.1) 86 (74.8) 
*Significantly different resistance (P < 0.05) compared with C. jejuni  
 
were resistant to all nine drugs tested. Of the 115 C. coli isolates, 89 (77.3%) were 
resistant to two or more antimicrobial agents, 63 (54.7%) were resistant to three or more 
drugs, and 5（4.3%） were resistant to five antibiotics (Table 3). None of the C. coli 
isolates were resistant to six or more antimicrobial agents included in the MIC test. Only 
one C. jejuni isolate was co-resistant to both ciprofloxacin and erythromycin, while none 
of the C. coli isolates displayed co-resistance to these two antibiotics (Table 3). The most 
common multidrug resistance pattern was to ciprofloxacin, nalidixic acid, and 
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tetracycline, which was observed in ~30% of C. jejuni and 50% of C. coli isolates, 
respectively (Table 3).  
Table 3. Multidrug resistance patterns among C. jejuni and C. coli isolates from feedlot 
cattle 
Antimicrobial agent C. jejuni (n=320) C. coli (n=115) Total (n=435) 
TN 2 (0.6%) 4 (3.5%) 6 (1.4%) 
CNT 97 (30.3%) 58 (50.4%) 155 (35.6%) 
CNTG 1 (0.3%) 0 1 (0.2%) 
CNTFL 1 (0.3%) 5 (4.3%) 6 (1.4%) 
CNTAEI 1 (0.3%) 0 1 (0.2%) 
A, Azithromycin; C, Ciprofloxacin; E, Erythromycin; T, Tetracycline; F, Florfenicol; N, 
Nalidixic acid; I, Telithromycin; L, Clindamycin. 
 
Genetic diversity of FQR Campylobacter from cattle  
     To determine if FQR Campylobacter isolates are genetically related, we analyzed the 
genetic diversity of representative isolates using PFGE and MLST.  A total of 26 FQR C. 
coli isolates were randomly selected for this purpose. Based on the 90% similarity level, 
the 26 isolates were grouped into five separate clusters, with the vast majority of isolates 
(76.9%, 20/26) grouped in cluster I, two isolates in cluster II and IV and one isolate in 
each of the remaining two clusters (Fig. 1a).  The first four clusters had closely related 
PFGE profiles; the only noticeable difference among the patterns was the presence of 
extra one or two bands in some isolates (Fig.1a). The 26 C. coli isolates tested came from 
15 different feedlot cattle farms in five different states that were sampled at different 
times. The 20 strains that grouped together in cluster I included those from 11 different 
farms in three different states,10 from Colorado, 6 from Kansas, 4 from Texas while 
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those in Cluster II were from 2 different farm in two states, the two isolates in Cluster IV 
came from the same farm in Missouri. MLST showed that the isolates grouped in cluster 
I, II, III and IV had the same sequence type (ST-1068), while the isolate in cluster V was 
ST-5446. 
     Additionally, 24 FQR C. jejuni isolates were examined for genetic diversity via PFGE. 
In contrast to the situation with C. coli, no predominant genotypes were observed among 
the C. jejuni isolates. There were a total of 17 different PFGE profiles using 90% 
similarity as the cut off (Fig. 1b). MLST analysis of 7 C. jejuni isolates (Ks-3-Fc-56, Co-
4-Fc-1, Co-1-Fc-22, Ks-4-Fc-1, IA-5-Fc-63, IA-3-Fc-18, Mo-1-Fc-27) representative of 
different PFGE pattern showed 6 different sequence types (ST982, ST3855, ST219, 
ST45, ST6751, ST459, ST3855 respectively). The MLST result confirmed the genetic 
diversity of FQR C. jejuni isolates. All together the PFGE and MLST findings suggest 
that clonal expansion is not involved in dissemination of FQR C. jejuni on the cattle 
farms. 
Antibiotic resistance mechanism of FQR Campylobacter  
     In Campylobacter, FQ resistance is conferred by point mutations in the gyrA gene in 
conjunction with the function of the CmeABC efflux pump.26 To examine the 
mechanisms of FQ resistance, the quinolone resistance determining region (QRDR) in 
gyrA of 27 FQR C. coli and 27 FQR C. jejuni isolates were sequenced to determine the 
mutations associated with FQ resistance.  These isolates were selected to represent all 
farms that were positive with FQR Campylobacter. All C. coli isolates harbored a single 
Thr-86-Ile mutation in GyrA without any other nucleotide changes in this region (Table 
4). Among the 27 FQR C. jejuni isolates sequenced in this study, 10 isolates had the Thr-
 
 
 
 
 
 
Fig. 1. Dendrogram constructed using the PFGE patterns of KpnI digested FQR C. coli (Fig. 1a) and C. jejuni (Fig. 1b) isolates. 
Numbers of bootstraps represent similarity. Clusters are determined using a cut off of 90% similarity. Isolate names are listed 
on the right side of each dendrogram. Tx: Texas; Co: Colorado; IA: Iowa; Ks: Kansas; Mo: Missouri; Fc: Feces.  
7
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86-Ile point mutation only, 8 isolates carried the Thr-86-Ile mutation plus the Arg-285- 
Lys mutation or the Asn-203-Ser change, and 7 isolates carried theAsn-203-Ser and Arg-
285-Lys mutations, one of which had an additional Ser-22-Gly change. Interestingly, 2 
FQR C. jejuni isolates had no point mutations in QRDR. (Table 4, Table S1). Ser-22-Gly 
and Arg-285-Lys substitution have not been previously reported to be associated with FQ 
resistance in Campylobacter. However, Arg-285-Lys mutation was also found in 
ciprofloxacin susceptible isolates, indicating this point mutation alone would not confer 
FQ resistance.  
     Additionally, we analyzed the resistance determinant for tetracycline resistance using 
a tet(O)-specific PCR. Among the 20 tetracycline-resistant Campylobacter isolates 
examined in this study, all were positive with tet(O), indicating it is responsible for the 
resistance phenotype. 
Table 4. Point mutations observed in the QRDR of GyrA in FQR C. jejuni (n = 27) and C. 
coli (n = 27) isolates 
Species Mutation(s) 
Ciprofloxacin 
MIC (μg/ml) 
No. of isolates 
C. jejuni Thr-86-Ile 8-32 10 
 
Thr-86-Ile     Arg-285-Lys 4-64 5 
 
Asn-203-Ser   Arg-285-Lys 8-64 6 
  Thr-86-Ile     Asn-203-Ser  16-32 3 
 Ser-22-Gly Asn-203-Ser Arg-285-Lys 16 1 
 
NF 4-16 2 
C. coli Thr-86-Ile 8-16 27 
NF: no point mutation found in gyrA 
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Discussion 
Results from this study revealed high prevalence of FQR Campylobacter in feedlot 
cattle in the U.S.  The resistance rate in C. coli is especially high, reaching to 77%. Such 
a high-level prevalence of FQ resistance in ruminants was not reported in earlier studies 
conducted in the U.S.,19-21 although a recent study conducted in 200825 found that 27.3% 
C. jejuni and 49.2% C. coli from different types of cattle productions (including both 
feedlot cattle and adult cows) were resistant to ciprofloxacin. Our findings in this study 
showed an even higher frequency of resistance to ciprofloxacin (35.4% in C. jejuni and 
77.3% in C. coli) and nalidixic acid (34.3% in C. jejuni and 82.6% in C. coli). All 
together, these observations clearly indicate a rising trend of FQR Campylobacter in 
ruminants in the U.S. The reason that FQ resistance was much more prevalent in C. coli 
than in C. jejuni is unknown, but it has been known that C. coli  is more likely to acquire 
antibiotic resistance than C. jejuni.23,27-30 
     Campylobacter is highly mutable, and multiple independent studies including our 
work have demonstrated the rapid emergence of FQR mutants in animals originally 
infected with FQS C. jejuni and then treated with an FQ antimicrobial.2,31-34 FQR mutants 
spontaneously occur in Campylobacter populations and use of FQ antimicrobials selects 
and enriches these mutants. In Campylobacter, FQ-resistance is mainly mediated by point 
mutations in the QRDR of DNA gyrase (GyrA) in conjunction with the function of the 
multidrug efflux pump CmeABC.2,26,35,36 The most frequent mutation observed in FQR  
Campylobacter isolates is Thr-86-Ile, followed by Asp-90-Asn, Thr-86-Lys, Thr-86-Ala, 
Thr-86-Val, Asp-90-Tyr and Ala-70-Thr.2,37,38 The Thr-86-Ile mutation confers a high 
level of FQ resistance (ciprofloxacin MIC ≥ 16 µl/ml) in Campylobacter, while other 
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mutations are associated with a low to medium level of resistance (MIC = 1-8 
µg/ml).2,39,40  Double mutations including Thr-86-Ile/Pro-104-Ser and Thr-86-Ile/Asp-90-
Asn have also been linked to FQ resistance in Campylobacter.39 
     Consistent with the previous findings discussed above, we found in this study that the 
FQR C. coli and C. jejuni isolates. However, we also identified three additional amino 
acid substitution in the C. jejuni isolates. One is Asn-203-Ser, which is known to confer 
FQ resistance along with Thr-86-Ile mutation.27,41 Another one is Arg-285-Lys, which 
alone may not confer FQ resistance because it was identified in susceptible strains. Six 
FQR contained both Asn-203-Ser and Arg-285-Lys, but no Thr-86-Ile (Table 4; Table 
S1). Whether the two mutations alone were responsible for the FQ resistance phenotype 
is unknown and needs further investigation. The third mutation is Ser-22-Gly, which has 
not been associated with FQ resistance in Campylobacter. Interestingly, two FQR C. 
jejuni isolates from the same farm did not show any mutations in QRDR of gyrA (Table 
4), and what is responsible for their resistance to FQ is unknown and can't be explained 
by mutations in gyrA. These findings indicate that the gyrA mutations in FQR C. jejuni 
isolates are more diverse than in FQR C. coli isolates. 
     FQ antibiotics are frequently used in veterinary medicine for the treatment and control 
of infectious diseases of pets and food-producing animals.42 For example, enrofloxacin 
and danofloxacin are approved as an injectable solution (various dosage regimens) for 
use in the treatment and control of respiratory disease in cattle associated with 
Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma 
bovis in the United States and many other countries.42 The initial approval of 
enrofloxacin by FDA was in 1998 and it was only for the treatment of bovine respiratory 
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disease (BRD) in beef cattle. Subsequent approvals extended their use for BRD treatment 
in dairy replacement heifers of less than 20 months of age in 2008, and their 
metaphylactic use for control of BRD in beef and non-lactating dairy cattle at high risks 
of developing BRD in 2012. About 43% of the feedlots included in the Feedlot 2011 
NAHMS study reported therapeutic use of FQs in approximately 42% of cattle with 
respiratory disease.43 In the United States, the use of these drugs in cattle production is 
permitted only under a prescription from a veterinarian and their extralabel use in food 
producing animals is strictly prohibited. In this study, we showed a substantial increase in 
the prevalence of FQ resistance in Campylobacter isolates from cattle in the U.S, which 
coincides with the expanded use of FQ antibiotics in cattle production. However, it is still 
unknown if the on-farm use directly influences the development and dissemination of 
FQ-resistant Campylobacter and if the treatment regimen can be managed to reduce the 
development and prevalence of FQ-resistance. 
     Except for FQs and tetracycline, the Campylobacter isolates examined in this study 
are generally susceptible to other tested antimicrobials (Table 2). For example, the 
resistance to macrolide (erythromycin) was barely detected in both C. coli and C. jejuni. 
Tetracycline has been used for animal production for many years, and we found that 
tetracycline resistance is high in both C. jejuni (88.1%) and C. coli (74.8%), which is 
even higher than previously reported.19,20,44 The predominant tetracycline resistance 
determinant in Campylobacter is tet (O), although a recent study reported that tet (A) also 
conferred resistant to tetracycline in Campylobacter.45 In this study, all examined 
tetracycline-resistant isolates harbored the tet(O) gene, consistent with previously 
reported findings. 
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     PFGE and MLST are two commonly used genotyping methods for differentiation of 
Campylobacter isolates.46-48 In this study, PFGE typing of 26 FQR C. coli and 24 FQR C. 
jejuni revealed that C. coli is more clonal than C. jejuni (Figure 1), despite the fact that 
the C. coli isolates were from 15 feedlots in 5 different states. The majority of the PFGE-
typed C. coli isolates were grouped into three clusters (I, II and IV) of high genetic 
similarity, which was confirmed by MLST to be a single ST (ST-1068), suggesting 
dissemination of a single clone on different cattle farms. This ST was observed in 83% 
(52/63) of the C. coli isolates of cattle origin in another report,49 further indicating that it 
is highly prevalent in cattle. The presence of C. coli with identical genotype on multiple 
geographically distant farms implies the dissemination of a single strain from farm to 
farm, which could be a potential factor driving the increase in FQR prevalence in 
Campylobacter. Similar findings were reported in a previous study, in which multiple 
antibiotic resistant C. coli collected from different cattle farms and at different times had 
an indistinguishable PFGE pattern, in contrast to the genetic diverse of C. jejuni 
isolates.50  The exact vehicles or mechanisms promoting clonal dissemination of C. coli 
in different cattle farms are unknown and need to be further investigated. For the C. 
jejuni isolates examined in this study, they are genetically diverse and it is unlikely that 
colonal expansion is involved in their dissemination. 
     In summary, we observed high prevalence of FQ-resistance in both C. jejuni and C. 
coli isolates derived from cattle in the U.S.  The reason for this rising trend in FQ 
resistance is uncertain, but it is likely due to the hyper-mutable nature of Campylobacter 
and the selection from use of FQ antimicrobials in the control of respiratory diseases in 
cattle production.  Additionally, clonal expansion, as reported in other studies,51-53  may 
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have also contributed to the increasing prevalence of FQR Campylobacter. Development 
of FQ resistance is known to affect the fitness of Campylobacter in chickens, resulting in 
persistence of FQR Campylobacter even in the absence of antibiotic selection pressure.54 
     Considering this possibility and the fact that FQs are currently used for cattle 
production, it is possible that the prevalence of FQR Campylobacter will continue to rise. 
Given that ruminant Campylobacter is a significant source of foodborne 
campylobacteriosis in humans, heightened efforts are needed to control the development 
and dissemination of FQR Campylobacter in cattle production. 
Methods and materials 
Sample collection and bacterial isolation 
     A total of 3,184 cattle fecal samples were collected from 35 different feedlot cattle 
herds located in Iowa (n=8), Texas (n=8), Colorado (n=8), Missouri (n=3) and Kansas 
(n=8) on two different occasions during December 2012 to March 2013. Collection of 
cattle fecal samples followed methods that have been described previously.55 Cattle fecal 
samples were collected from the floor of animal pens and only freshly voided fecal pats 
were sampled.  In other words, the sample was collected from a fecal pat only after a cow 
was observed defecating.  This procedure allowed us to standardize environmental 
exposure time among fecal samples and estimate herd prevalence of Campylobacter 
without confining animals for collection of rectal samples.  Freshly voided fecal pats 
were scraped with a sterile cotton tipped swab and the swab was immediately placed in 
10 ml glass tubes containing Campylobacter Thioglycollate Broth (CAMPY-THIO).  
Vials were labeled and then immediately placed in an electric cooler set to 4 ºC.  All 
cattle fecal samples were shipped priority overnight to the testing laboratory.  All samples 
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were shipped, in insulated boxes packed with Ice-Brix® (Polar Tech Industries, Genoa, 
IL 60135).  Only samples received by the laboratories within 24 hours of the date of 
collection were screened for Campylobacter.  From the Campy-Thio containing the fecal 
samples, 1 ml was added into tubes containing 9 ml of Campylobacter enrichment broth 
(Mueller–Hinton [MH] medium supplemented with selective growth supplements 
[SR084E and SR117E; Oxoid]), and incubated at 42 °C for 48 h under microaerobic 
conditions (5% O2, 10% CO2, and 85% N2). From the enrichment culture, an inoculum of 
100 µl was streaked onto MH agar containing the same selective supplements, which 
were further incubated for 48 h under the same conditions. A single Campylobacter-like 
colony from each sample was subcultured onto a MH agar plate and the pure cultures 
were stored in glycerol stocks at -80 °C until further use.  
Campylobacter identification 
     PCR was used to detect and differentiate C. jejuni and C. coli. Two sets of previously 
published PCR primers were used.56,57 The first primer pair (CCCJ-F: 5’-AAT CTA ATG 
GCT TAA CCA TTA-3’; CCCJ-R: 5’-GTA ACT AGT TTA GTA TTC CGG-3’), 
targeting 16S rRNA, was designed to co-identify C. jejuni and C. coli.56 The second 
primer pair (mapA-F: 5’-GAG TGC TTG TGC AAC TAA AC-3’; mapA-R: 5-’ATA 
GCA TCT TGA GTT GCT CC-3’) was specific for C. jejuni only.57 The primers were 
synthesized at the DNA facility in Iowa State University using the MerMade-192 
synthesizer. PCR reactions were performed as described previously.56,57 
Antimicrobial susceptibility testing 
     In total, 320 C. jejuni (5 from each feedlot) and 115 C. coli (3 from each feedlot) 
isolates were randomly chosen and included in the susceptibility testing. The minimum 
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inhibitory concentrations (MICs) of nine antibiotics were determined using a standard 
broth microdilution method as recommended by Clinical and Laboratory Standards 
Institute (CLSI) and National Antimicrobial Resistance Monitoring System for Enteric 
Bacteria (NARMS).58-60 Commercially available Sensititre Campylobacter plates (Trek 
Diagnostic Systems, Cleveland, Ohio) were used for antimicrobial susceptibility testing. 
The plates were read after incubated in a microaerobic environment for 24 h at 42 °C. 
The lowest antimicrobial concentration at which no bacterial growth developed was used 
as MIC value for each isolate. The antimicrobial resistance breakpoints were chosen 
according to the interpretive standards established by the CLSI for bacteria isolated from 
animals.58-60 C. jejuni ATCC 33560 and C. coli ATCC 33559 were used as quality 
control strains for C. jejuni and C. coli, respectively. 
PFGE and MLST typing of Campylobacter isolates 
     In total, 26 FQR C. jejuni and 24 FQR C. coli isolates were randomly chosen from 
different feedlots in different states. In this study, 15 feedlots were positive with FQR C. 
coli, and 17 feedlots were positive with FQR C. jejuni. We selected 1-2 isolates from each 
positive feedlot to represent all positive farms in all five states. PFGE analysis of the 
macrorestriction fragment patterns of genomic DNA using KpnI enzyme was performed 
on these isolates following the CDC’s standardized PulseNet protocol for Campylobacter 
with minor modifications.47 Briefly, fresh cultures of Campylobacter were embedded in 
1% Seakem Gold agarose (Fisher Scientific, Fair Lawn, NJ) and lysed with proteinase K 
for 1 h at 55 °C in a water bath shaker. The gel plugs were digested with KpnI for 4 h at 
37 °C. Digested plugs were embedded into 1% agarose and separated by electrophoresis 
in 0.5 × TBE buffer (Promega) at 14 °C for 18 h using a Chef Mapper electrophoresis 
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system (Bio-Rad, Hercules, CA).  Gel was stained with ethidium bromide for 30 min and 
then photographed by UV transillumination (Alpha Innotech, Santa, Clara, CA). The 
PFGE patterns were analyzed by the GelCompare II v.6.5 software program (Applied 
Maths, Kortrijik, Belgium) using Dice similarity coefficient and unweighted-pair group 
method with arithmetic averages (UPGMA) with 0.5% optimization and 1.5% position 
tolerance. Lambda DNA ladder (Bio-Rad) was used as the molecular size marker.  
     To further confirm the genotype of those isolates, MLST, originally developed by 
Dingle et al.,46 was carried out on FQR C. coli and C. jejuni isolates representative of 
different PFGE types. Seven housekeeping genes were amplified and sequenced using the 
primer sets recommended at the Campylobacter MLST website 
(http://pubmlst.org/campylobacter/), developed by Keith Jolley and Man-Suen Chan at 
the University of Oxford.61 All PCR products were purified using the QIAquick® PCR 
purification kit (QIAGEN, Hilden, Germany) and then sequenced at the DNA Core 
Facility of Iowa State University using an Applied Biosystems 3730xl DNA Analyzer. 
Allelic numbers were assigned to the isolates by performing BLAST searches for the 
assembled sequences using the single-locus query function, whereas sequence types were 
assigned using the allelic profile query function in the MLST database. Sequences that 
were identical to existing alleles in the MLST database were assigned the corresponding 
allele numbers. Novel sequences were assigned new allele numbers and sequence types 
(STs) within the MLST database. 
Antibiotic resistance mechanism determination   
      A total of 27 FQR C. coli and 27 FQR C. jejuni isolates were selected for 
determination of the point mutations in gyrA (Table. S1). To amplify the QRDR region of 
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gyrA by PCR, primers GyrAF1 (5’-CAACTGGTTCTAGCCTTTTG-3’) and GyrAR1 
(5’-AATTTCACTCATAGCCTCACG-3’) were used for C. jejuni, while GyrAF2 (5’-
TTATTTAGATTATTCTATGAGCGT-3’) and GyrAR2 (5’-
CTTGAGTTCGATTACAACAC-3’) were used for C. coli. All PCR products were 
purified using the QIAquick® PCR purification kit (QIAGEN, Hilden, Germany) and 
then sequenced at the DNA Core Facility of Iowa State University using an Applied 
Biosystems 3730xl DNA Analyzer.  
     The presence of the tet(O) gene (the predominant determinant of tetracycline 
resistance in Campylobacter), was determined by PCR. For this purpose, primers tet(O)-F 
(5’-GGCGTTTTGTTTATGTGCG -3’) and tet(O)-R (5’-
ATGGACAACCCGACAGAAGC-3’) were used to amplify a 559-bp region of the tet(O) 
gene as described elsewhere.47 
Statistical analysis 
     To compare the prevalence of antimicrobial resistance between C. jejuni and C. 
coli, the statistical analyses were performed with GLIMMIX procedure in SAS 9.4 
version (SAS Institute Inc., Cary, NC, USA) for binary distribution (yes/no response 
variable) with logit link function. Both states and farms were considered as random 
effects, the Campylobacter species (C. jejuni and C. coli) was the fixed effect, and three 
different models were fitted separately with three kinds of antibiotics (ciprofloxacin, 
nalidixic acid and tetracycline) as response variables. The significance level used here 
is 0.05. 
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Objectives: To identify and characterize a novel cfr variant that recently emerged and 
confers multidrug resistance in Campylobacter, a major foodborne pathogen. 
Methods: Whole genome sequencing was initially used to identify the cfr(C) gene in 
Campylobacter isolates and its function was further verified by cloning into an antibiotic-
susceptible C. jejuni strain. Distribution of cfr(C) in various Campylobacter isolates was 
determined by PCR analysis. Genotyping of cfr(C)–positive strains was done by pulsed 
field gel electrophoresis and multi-locus sequence typing.  
Results: The cfr(C) gene is predicted to encode a protein that shares 55.1% and 54.9% 
identity with Cfr and Cfr(B), respectively. cfr(C) was located on a conjugative plasmid of 
~48 kb.  Cloning of cfr(C) into C. jejuni NCTC11168 and conjugative transfer of the 
cfr(C)-containing plasmid confirmed its role in conferring resistance to phenicols, 
lincosamides, pleuromutilins, and oxazolidinones, and resulted in 8- to 256-fold increase 
in their MICs in both C. jejuni and C. coli. The cfr(C) gene was detected in multiple C. 
coli (34/344; 10%) isolates derived from different cattle farms in different states, and 
molecular typing of the cfr(C)-positive C. coli isolates revealed its spread mainly via 
clonal expansion. 
Conclusion: These results identify cfr(C) as a new multidrug resistance mechanism in 
Campylobacter and suggest the potential transmission of this mechanism via the 
foodborne route, warranting enhanced efforts to monitor its spread in Campylobacter and 
other foodborne pathogens. 
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INTRODUCTION 
     The cfr gene, encoding an rRNA methyltransferase, confers resistance to five 
chemically unrelated antimicrobial classes including phenicols, lincosamides, 
oxazolidinones, pleuromutilins, and streptogramin A (known as the PhLOPSA 
phenotype).1 Of particular concern is the resistance to the oxazolidinone class (e.g. 
linezolid), which is used as the last resort for treating multi-drug resistant Gram-positive 
bacterial infections in human.2 Since its first discovery in bovine Staphylococcus sciuri 
isolate in 2000, the cfr gene has been detected in a variety of Gram-positive and Gram-
negative bacteria.3-7 The cfr gene was often found on transferable plasmids with 
additional antibiotic resistance genes, which further facilitates its dissemination and 
emergence in different bacterial species and genera.8-11 A cfr-like gene, cfr(B), have 
recently been discovered in mobile genetic element in both Peptoclostridium difficile and 
Enterococcus faecium of human origin, conferring the same multidrug resistance 
phenotype and sharing 74.9% identity in amino acid (aa) sequences with the original 
Cfr.12, 13   
     Thermophilic Campylobacter (including Campylobacter jejuni and Campylobacter 
coli) are major foodborne pathogens and leading bacterial causes of gastroenteritis in the 
United States and other countries.14, 15 Campylobacter is commonly present in food 
producing animals, and in addition to poultry, ruminants are important reservoirs for this 
pathogenic organism.16 Ruminant Campylobacter can be transmitted to humans via 
contaminated milk and water, environmental contamination, and direct contact with 
animals.16-18 
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     Antimicrobial resistance in Campylobacter, compromising the clinical treatment of 
campylobacteriosis, has become in recent years a major public health concern in both 
developed and developing counties.14, 19-22 Indeed, the 2013 CDC report classified drug-
resistant Campylobacter as a serious antibiotic resistance threat in the U.S.
（https://www.cdc.gov/drugresistance/threat-report-2013/）.  Several mechanisms 
conferring resistance to clinically important antibiotics have been described in 
Campylobacter, including mutations in target genes, such as gyrA mutations to 
fluoroquinolones and 23S rRNA mutations to macrolides,23, 24 multidrug efflux pump 
CmeABC extruding structurally diverse compounds and antimicrobial,25 and horizontally 
acquired antibiotic resistance genes, such as tet(O) and aphA-3.26 Recently, a ribosomal 
RNA methylase gene erm(B) conferring high-level resistance to macrolide was identified 
in both C. jejuni and C. coli.27, 28 
     As a foodborne pathogen, Campylobacter is exposed to antimicrobials used for both 
food animal production and hu8man medicine. In the United States, florfenicol is 
currently indicated for the treatment of bovine and swine respiratory disease, serving as a 
selection force for florfenicol-resistant organisms in food producing animals. Although 
the cfr gene has been identified in both Gram-positive and Gram-negative organisms, it 
has not been reported in foodborne pathogens including Campylobacter. In this study, a 
novel plasmid borne cfr-like gene, designated cfr(C) [the nomenclature was approved by 
the Nomenclature Center for MLS Genes curated by Marilyn C. Roberts at University of 
Washington], was identified in multidrug resistant C. coli isolates of cattle origin. The 
cfr(C) gene was found to confer transferable resistance to oxazolidinones (linezolid) and 
phenicols (chloramphenicol and florfenicol) as well as lincosamides and pleuromutilins 
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(Campylobacter is naturally resistant to streptogramin) in both C. jejuni and C. coli. To 
the best of our knowledge, this is the first report of a novel cfr-like gene in a foodborne 
pathogen. 
MATERIALS AND METHODS 
Bacterial isolates and detection of florfenicol resistance genes 
     During a surveillance study of antimicrobial susceptibility of Campylobacter isolates 
from feedlot cattle farms in five different States in the U.S., a large number (2,220) of 
Campylobacter isolates were obtained from fecal samples. These isolates were identified 
as either C. jejuni or C. coli by species-specific PCR as described previously.29, 30 Tx40, a 
C. coli isolate from the collection, exhibited elevated MICs of florfenicol and 
chloramphenicol. To detect if Tx40 harbored known florfenicol-resistance genes (cfr, 
florR, fexA, fexB) or the G2073A mutation in 23s rRNA, PCR reactions were conducted 
using primers specific for the target genes or mutations as described previously.4, 31-34 
     For screening the distribution of cfr(C) in different Campylobacter isolates, PCR was 
designed to detect an internal fragment of the cfr(C) gene among C. jejuni (n=1886) and 
C. coli (n=344) isolates from feedlot cattle using primers cfr(C)-F (5’- 
GGTGAAACTGTTGTGGAGAT-3’) and cfr(C)-R (5’- 
AGTTTCCGTAACTGTCGTTT-3’). The expected size of PCR product was 722 bp. All 
isolates carrying the gene of interest were investigated for their chloramphenicol 
susceptibility, PFGE patterns, and MLST types.  
Transfer of florfenicol resistance by conjugation 
     C. jejuni JL272 is an erythromycin-resistant (EryR) derivative of NCTC 11168 and 
carries an A2074G mutation in the 23S rRNA gene, conferring a high-level erythromycin 
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resistance (MIC = 1024 mg/L).35 To determine if the florfenicol resistance in C. coli 
Tx40 was transferrable between Campylobacter species, a conjugation experiment was 
performed as described before.36 Briefly, the florfenicol-resistant C. coli Tx40 was used 
as the donor strain, and EryR but florfenicol-susceptible C. jejuni JL272 was used as the 
recipient strain. Transconjugants were selected on Mueller-Hinton (MH) agar plates 
containing 4 mg/L florfenicol and 30 mg/L erythromycin. Conjugation without the donor 
strain served as a negative control. The transconjugants were analyzed for antimicrobial 
susceptibility in comparison with the donor and recipient isolates.  
S1 nuclease PFGE 
     To detect the presence and size of plasmid pTx40, the three Campylobacter strains, 
including C. coli Tx40, transconjugant JL272/pTx40, and C. jejuni JL272, were analyzed 
by S1 nuclease PFGE as described previously.37 Briefly, the agarose plugs containing 
Campylobacter isolates were digested with S1 nuclease (Sigma) in 200 µL of 50 mM 
NaCl, 30 mM sodium acetate (pH 4.5), and 5 mM ZnSO4 at 37℃ for 45 min. The 
digested and undigested plugs were embedded into 1% agrose gel. Electrophoresis was 
conducted for 18h in 0.5 × TBE buffer. Gel was stained with ethidium bromide and 
distained with distilled water. Gel image was taken with a digital imaging system.38  
Whole genome sequencing and plasmid analysis 
     Genomic DNA of C. coli Tx40 and transconjugant JL272/pTx40 were purified using 
Wizard® genomic DNA purification kit (Promega, Madison, USA). The purified 
genomic DNA was submitted to the DNA facility of Iowa State University (USA) for 
library preparation using TruSeq DNA PCR-free library preparation kit. The whole 
genome sequencing was carried out utilizing the Illumina® Miseq instrument. The 
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generated reads were assembled de novo into contigs using the Velvet (v 1.2.10) and 
VelvetOprimiser (v 2.2.5).39 Genome annotation was performed using the RAST server.40 
The contigs of transconjugant JL272/pTx40 were aligned against the reference genome 
(NC_002163) of the recipient strain JL272 by using Mauve (v 2.3.1).41-43 The additional 
contig in transconjugant JL272/pTx40 was identified as plasmid pTx40. The plasmid 
sequence was closed by regular PCR and DNA sequencing, and annotation was further 
confirmed using the BLAST program Blastn, Blastp (NCBI) and DNAPlotter software.44 
The draft genome sequences of C. coli Tx40 were aligned and then used for phylogenetic 
tree construction based on SNP alignment by Parsnp in the Harvest package.45 The 
phylogenetic tree was visualized with FigTree (http://tree.bio.ed.ac.uk/software/figtree). 
Cloning of cfr(C) into E. coli and C. jejuni by transformation and conjugation 
     To determine the role of cfr(C) in conferring florfenicol resistance, a 1,361bp DNA 
fragment was amplified from C. coli Tx40 isolate using primer cfr(C)-F (5’-
TGCTCTAGAATCAGGGAGGATATCGGG-3’) (XbaI), and cfr(C)-R (5’-
CCGGAATTCTGAGCGTTCTCTTTCGTG-3’) (EcoRI). This fragment includes the 
coding sequence of cfr(C) (1140 bp), as well as the 163 bp upstream sequence of the gene 
and 58 bp downstream sequence of the gene. The amplicon was digested with XbaI and 
EcoRI and ligated with an Escherichia coli-C. jejuni shuttle plasmid pRY10846 to 
construct plasmid pRY108-cfr(C). The pRY108-cfr(C) plasmid was then transformed 
into E. coli DH5α competent cells by chemical transformation. The E. coli transformants 
were selected from LB agar plates containing 30 mg/L kanamycin, and further confirmed 
for carrying plasmid pRY108-cfr(C) by PCR using the cfr(C) specific primers.  Plasmid 
pRY108-cfr(C) in E. coli was transferred into the C. jejuni NCTC 11168 isolate by 
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triparental conjugation as described previously.47 Transconjugants were selected on MH 
agar plates containing 30 mg/L kanamycin and selective supplements (Oxoid, 
Cambridge, UK). The presence of cfr(C) gene in the C. jejuni transconjugant was 
confirmed by PCR and DNA sequencing of the cfr(C) gene. 
Antimicrobial susceptibility testing 
     For antimicrobial susceptibility testing of Campylobacter isolates, the minimum 
inhibitory concentrations (MICs) of nine antibiotics were determined using Sensititre 
plates (Trek Diagnostic Systems, Thermo Fisher Scientific Inc., Cleveland, OH) as 
recommended by the manufacturer. The nine antibiotics include azithromycin, 
ciprofloxacin, erythromycin, gentamicin, tetracycline, florfenicol, nalidixic acid, 
telithromycin and clindamycin. To further investigate if cfr(C) confers a PhLOPSA 
resistance phenotype in Campylobacter, the parent isolate C. coli Tx40, its 
transconjugants and transformants, and the recipient strain were analyzed for 
susceptibility to chloramphenicol, florfenicol, linezolid, tedizolid, gentamicin, and 
clindamycin using broth microdilution as recommended by CLSI.48 C. jejuni ATCC 
33560 was used as a quality-control strain.   
Genbank accession numbers 
     The draft genome sequence of Tx40 and plasmid sequence of pTx40 have been 
deposited in GenBank under the accession number MDCN00000000 and KX686749, 
respectively. 
RESULTS 
Initial identification of a novel transferable florfenicol resistance determinant  
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     During our surveillance study of Campylobacter from feedlot cattle, we noticed that a 
C. coli isolate, Tx40, was resistant to multiple classes of antibiotics including 
ciprofloxacin, clindamycin, florfenicol, nalidixic acid, and tetracycline as analyzed by the 
Sensititre plate MIC testing method (Table. 1). Notably, this isolate exhibited a 
florfenicol MIC of 32 mg/L, which was rarely reported in Campylobacter. To understand 
why Tx40 was highly resistant to florfenicol, we performed PCR analysis of known 
florfenicol resistance mechanisms in this isolate. However, neither the reported 
florfenicol resistance genes including cfr, florR, fexA, fexB, nor the G2073A mutation in 
23s rRNA were detected in Tx40 (data not shown). Next, conjugation was carried out to 
determine the transferability of florfenicol resistance in Tx40. Interestingly, the resistance 
phenotype was transferable and the transconjugant, designated JL272/pTx40, exhibited 8- 
to 32- fold increase in the MICs of chloramphenicol and florfenicol compared with the 
recipient strain JL272 (Table 1). S1 nuclease PFGE revealed the presence of a plasmid 
with a size of ~ 48 kb in C. coli Tx40 and its transconjugant JL272/pTx40, but not in the 
recipient strain JL272 (Fig. 1). These results strongly suggested that a previously 
undescribed florfenicol resistance gene was present on a conjugative plasmid, named 
pTx40, in C. coli Tx40. 
Sequences of plasmid pTx40 and the novel gene cfr(C)  
     To identify the previously uncharacterized florfenicol resistance gene, the whole 
genome of C. coli Tx40 and its transconjugant JL272/pTx40 were sequenced. The draft 
genome of C. coli Tx40 is 1,718,047 bp in length, with a GC content of 31.3%. 
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Table 1. Antimicrobial susceptibility profile of key Campylobacter strains analyzed in this study 
 MICs (mg/L) for different bacterial isolates 
Antimicrobial 
agent 
C. jejuni        
11168 
C. jejuni        
JL272 
C. coli 
Tx40 
C. jejuni 
JL272/pTx40 
C. jejuni          
11168/pRY108 
C. jejuni 11168/pRY108 
-cfr(C) 
Azithromycin 0.03 >64 0.12 >64 0.03 0.03 
Ciprofloxacin 0.06 0.06 16 0.06 0.06 0.06 
Erythromycin 0.25 >64 1 >64 0.25 0.12 
Gentamicin 0.5 0.5 0.5 0.25 0.5 0.5 
Tetracycline 0.12 0.12 >64 64 0.06 0.06 
Clindamycin 0.06 >16 >16 >16 0.06 >16 
Chloramphenicol 0.5 1 8 8 0.5 4 
Florfenicol 1 0.5 32 16 1 16 
Linezolid 4 8 128 >128 8 128 
Tedizolid 4 8 8 8 4 4 
Tiamulin <1 <1 128 >128 <1 128 
 
Annotation of the draft sequence indicated the presence of 1,787 putative coding sequences on the chromosome and 37 detected 
tRNAs. Sequences analysis showed that C. coli Tx40 encodes many of the common virulence factors involved in adherence, 
invasions, motility, immune evasion, and toxins in Campylobacter, such as CadF, MOMP, PEB1, CiaB, Flagella, LOS, N-linked 
9
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glycosylation system, O-linked glycosylation system, and CDT.  The assembled draft 
genome of C. coli Tx40 is 99% identical to those of both C. coli strain RM5611 and 
HC2-48 in the NCBI database (Fig. 2A), except for an additional putative prophage 
consisting of 5 extra contigs (~32 Kb in total). Both RM5611 and HC2-48 were isolated 
from cattle as indicated in the NCBI database. We also assembled the genome of 
transconjugant JL272/pTx40. To determine the sequence of the acquired plasmid pTx40, 
we aligned the contigs of transconjugant JL272/pTx40 to the genome of the recipient 
strain C. jejuni JL272, which is identical to C. jejuni NCTC 11168 except for the 
A2074G mutation in 23S rRNA gene.35 
 
Figure. 1. PFGE analysis of undigested and S1-digested Campyloabter DNA, arrows 
indicate the location of plasmid pTx40. Lane M, lambda DNA ladder (Biorad); Lane 1, 
undigested C. coli Tx40; Lane 2, S1 digested C. coli Tx40; Lane 3, undigested 
transconjugant JL272/pTx40; Lane 4, S1 digested transconjugant JL272/pTx40; Lane 5, 
undigested C. jejuni JL272; Lane 6, S1 digested C. jejuni JL272. 
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Interestingly, an additional contig of 48,144 bp was found in JL272/pTx40 and it was 
absent in the genome of the recipient strain C. jejuni JL272. The size of the contig is 
consistent to what we estimated by the S1 nuclease PFGE analysis (Fig. 1).  Additionally, 
strain Tx40 contained the same contig as the one in transconjugant JL272/pTx40. Then a 
PCR reaction using a primer pair located at both ends of the 48,144 bp contig yielded an 
expected product, which confirmed the circular form of this fragment. Therefore, the 
additional contig in C. jejuni transconjugant JL272/pTx40 represents the full sequence of 
the conjugative plasmid pTx40, which was acquired from C. coli Tx40 isolate via 
conjugation. 
     Plasmid pTx40 was annotated to encode 47 open reading frames (ORFs), among 
which 25 ORFs encode hypothetical proteins, while the other 22 ORFs encode proteins 
with known functions,  including genes related to plasmid replication (repA), 
antimicrobial resistance (tet(O), aphA-3), conjugative transfer (traC, trbL, traJ) and 
plasmid maintenance (cotH). Among these ORFs, there is a putative gene of 1,140 bp in 
length encoding a 379 aa protein, showing high similarity to the sequences of S-
adenosylmethionine (SAM) enzyme superfamily, which includes the Cfr protein. The N-
terminal 352 aa were almost identical to the corresponding part of a ribosomal RNA large 
subunit methyltransferase N from both C. difficile F548 (Genbank accession no. 
WP_021434980) and C. difficile P1 (Genbank accession no. WP_021416053). 
Interestingly, the 379 aa putative protein only shows 55.1% or 54.9% identity to the 
original Cfr (Genbank accession no. CAC04525.1) from Staphylococcus sciuri4 or the 
recent reported Cfr(B) (Genbank accession no. AKV84429.1) from E. faecium (Fig. 3),13 
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respectively. Therefore, we hypothesized that the 1,140 bp putative gene, designated 
cfr(C), encodes a novel Cfr(C) protein, conferring multidrug resistance in 
Campylobacter.  
Function of cfr(C) in conferring the PhLOPSA phenotype 
       To determine the function of cfr(C), its encoding sequence along with the promoter 
region was amplified from Tx40 and cloned into shuttle plasmid pRY108.46 The 
construct pRY108-cfr(C) was successfully transferred into C. jejuni NCTC 11168 by 
triparental conjugation. The parent strain, the recipient, and the transconjugant were 
assayed for their susceptibility to PhLOPSA antimicrobials. Due to the intrinsic resistance 
of Campylobacter to streptogramin, the MIC of streptogramin was not determined, while 
the susceptibilities to other four antimicrobial classes (phenicols, lincosamides, 
oxazolidinones and pleuromutilins) were tested (Table 1). The control strain, which was 
NCTC11168 carrying an empty pRY108 plasmid, did not change the susceptibility to the 
tested antimicrobials. However, C. jejuni NCTC11168 carrying pRY108-cfr(C) showed 
significantly elevated MICs of the tested antibiotics (Table 1), including chloramphenicol 
(8-fold), florfenicol (16-fold), linezolid (16-fold), tiamulin (>128-fold), and clindamycin 
(>256-fold). The results clearly indicated that cfr(C) is functional in Campylobacter and 
encodes a novel Cfr(C) protein, contributing to the PhLOPSA resistance phenotype in 
Campylobacter. 
The genetic environment of cfr(C) gene in Campylobacter 
     The 48 Kb pTx40 plasmid is highly similar to the previously reported plasmids pCC31 
(~45Kb) and pN29710-1(~55Kb) in C. coli (Fig. 2B).36, 49 They shared the same 
conjugative plasmid backbone. Compared to the pCC31, pTX-40 has an extra 4,505 bp  
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segment containing the cfr(C) region, which was inserted between cpp2 and repA by 
replacing cpp3 and cpp4  (Fig. 2C). The backbone of pTX-40 has a GC content of 29.8%, 
which is close to the GC content of the C. coli chromosome. However, the insertion 
segment has a GC content of 43.8%, indicating that it was exogenously acquired by 
Campylobacter. The insertion segment contained six ORFs, and four of them encode 
antimicrobial resistant determinants including a hygromycin resistant gene (hph), an 
aphA-3, a truncated streptomycin adenyltransferase (aadE) and  the cfr(C) gene (Fig. 
2C). The segment, except for the cfr(C) gene, is present in pN29710-1, which contained  
an additional gene encoding an acetyltransferase and a full-length adenyltransferase 
encoding region, in contrast to a truncated one in pTx40.  Compared to pN29710-1, 
cfr(C) in pTx40 was inserted downstream of ahpA-3 and replaced two hypothetical genes 
in pN29710-1 (Fig. 2C).  
Distribution of cfr(C) in Campylobacter isolates of bovine origin. 
     To assess the distribution of cfr(C), we conducted PCR analysis of Campylobacter 
isolates that were collected from 35 different feedlot cattle herds located in five states. 
Among the 1,886 C. jejuni and 344 C. coli isolates examined in this study, 34 C. coli 
isolates were positive for the cfr(C) gene and they were derived from 6 different farms in 
two states (Kansas and Texas). No cfr(C) was found in the examined C. jejuni isolates, 
indicating the prevalence of cfr(C) is much higher in C. coli isolates (34/344, 10.0%) than 
in C. jejuni isolates (0/1886, 0%). All cfr(C)-positive C. coli isolates exhibited 
chloramphenicol resistance (MIC >16 mg/L) and were subjected to PFGE analysis. All 
isolates except one showed the same PFGE pattern and shared the same MLST profile 
ST1068 with Tx40 (PFGE result is partly shown in Fig. S1), suggesting that clonal 
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expansion has been involved in the spread of cfr(C)-positive C. coli in feedlot cattle in 
the United States. 
 
 
Fig. 2.  Sequence analysis of C. coli Tx40 genome and pTx40. (A) The maximum-
likelihood whole genome SNPs tree showing the relationship of Tx40 to other C. coli 
strains with complete genome available in GenBank. The numbers along the branches of 
the tree denote percent occurrence of nodes among 100 bootstrap replicates. The scale bar 
represents the number of nucleotide substitutions per site. (B) Circular representation of 
BLAST comparisons between plasmids pTx40, pCC31, and pN29710-1. pTx40 was used 
as reference. GC content of pTx40 was plotted outward for values > 30.5 % (average) 
and inward for values < 30.5 % ( average).The pTx40 sequences absent in pCC31 and 
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pN29710-1 were shown by blank in the corresponding circle. (C) Detained comparison of 
the cfr(C) region in pTx40 with plasmid pCC31 from C. coli CC31 of human origin and 
pN29710-1 from C. coli CVM N29710 of retail meat origin. The arrows indicate the 
positions and direction of the transcription of the genes. The regions of homology are 
shaded grey based on the degree of homology. “Δ” indicates a truncated version of a 
gene. aad9: Streptomycin 3-adenylyltransferase. hph: Hyromycin resistance protein. 
aadE: Streptomycin aminoglycoside 6-adenyltransferase. sat4: Streptothricin 
acetyltransferase. 
 
DISCUSSION  
     To date, cfr is the only known gene conferring resistance to PhLOPSA antibiotics.
50 
Since it was firstly identified on plasmid pSCFS1 from S. sciuri of bovine origin in 2000, 
the cfr gene had been found on plasmids in different bacterial species including Bacillus, 
Enterococcus, Macrococcus, Jeotgalicoccus, Proteus and Escherichia.3-7  Additionally, 
the cfr gene has also been reported worldwide, including the United States, China, 
Germany, Denmark, Italy, Mexico, and Ireland.3-7, 51-54 The rapid dissemination of cfr 
poses a serious threat to antimicrobial therapy because it confers a multidrug resistance 
phenotype. In addition to cfr, a cfr variant, cfr(B), was recently reported in hospital 
isolates of E. faecium and P. difficile, which is also located on a mobile genetic element 
and confers a resistance profile similar to that of Cfr.13, 55  In this study, a novel cfr 
variant, cfr(C), was discovered in C. coli isolates of cattle origin. It was located on a 
conjugative plasmid (pTx40) and conferred a multidrug resistance pattern similar to that 
of the cfr gene.50, 56 To the best of our knowledge, this is the first report of a cfr-like gene 
found in foodborne pathogens. The finding of cfr(C) in Campylobacter is alarming 
because Campylobacter is one of the most common foodborne pathogens. Therefore, 
cfr(C) may be potentially transferred to human via the food chain, facilitating the 
transmission and spread of cfr(C) to other bacterial organisms. 
105 
 
 
 
     The emergence of cfr(C) in Campylobacter is possibly driven by use of florfenicol in 
cattle production. Thus cfr(C) may have facilitated Campylobacter adaptation in the food 
producing environment. Although florfenicol is not used for human medicine, acquisition 
of cfr(C) results in multidrug resistance. Of particular concern is its resistance to the 
oxazolidinone class of antibiotics (e.g. linezolid), which is used as the last resort for 
clinical treatment of multidrug resistant bacterial infections in human.57 Although 
linezolid is currently indicated for use in humans for the treatment of Gram-positive 
bacterial infections and not for campylobacteriosis, the cfr(C) gene in Campylobacter is 
carried by a conjugative plasmid (pTx40) and may be transferred to other organisms via 
horizontal gene transfer, posing a potential threat to clinical use of oxazolidinone 
antibiotics in humans.  
     It was shown under laboratory conditions that pTx40 was transferable between 
Campylobacter species by conjugation (Table 1 and Figure 1). Although it remains 
debatable whether conjugative plasmids of Campylobacter can be transferred to other 
bacterial genera,58 an early report demonstrated the successful transfer of a tet(O)-
carrying plasmid from C. jejuni to E. coli, suggesting that inter-genera dissemination is 
possible for conjugative Campylobacter plasmid.59 Several factors may facilitate the 
persistence and dissemination of the cfr genes. The use of florfenicol in animal 
production will continue to serve as a selection pressure for the spread of the cfr genes.  
Since the cfr genes confer a multidrug resistance phenotype, the use of other PhLOPSA 
antibiotics either in animal or human medicine will also facilitate the dissemination of cfr 
and its variants.  Additionally, the cfr genes co-exist on mobile vectors with other 
antibiotic resistance genes that confer resistance to non-PhLOPSA antibiotics [such as 
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tet(O) and aphA-3]. Thus use of other classes of antibiotics may also promote the 
prevalence and persistence of cfr-carrying plasmids and mobile elements, further 
facilitating the dissemination of the multidrug resistance mechanism.  
     In pTx40, the 4,505 bp segment containing cfr(C) was inserted upstream of repA, 
where is considered to be an insertion hotpot and could accommodate different 
segments.36 The cfr(C)-carrying segment was not found in other plasmids, but the first 
five genes of the segment as a whole are present in plasmid pN29710-1 with one 
hypothetic gene deleted (Fig. 2C). Compared to pCC31 and pN29710-1, the repA gene in 
pTx40 is 673 bp shorter (Fig. 2C), but the exact form of repA was also found in several 
other plasmids, such as pcjDM from C. jejuni strain T1-21 (Genbank accession 
no.CP013117) and pccdm1 from C. coli strain HC2-48 (Genbank accession no. 
CP013035). The fact that pTX40 can be transferred and maintained in transconjugants 
indicates that the repA gene is functional. The cfr(C) gene is unique to pTx40 and how 
the plasmid acquired the gene is unknown. Interestingly, the G + C content of the 4,505 
bp segment is well above that of the rest plasmid and also that of C. coli genome, 
suggesting that pTx40 acquired this insertional fragment exogenously. Detailed analysis 
of the inserted fragment in pTx40 did not identify insertion sequences or transposable 
elements. Thus, how cfr(C) was inserted into pTx40 is still unknown. Regardless, given 
that it is carried by a conjugative plasmid, it is possible that cfr(C) will continue to spread 
in Campylobacter and beyond.  
     Cfr homologs are present in both Gram-positive and Gram-negative bacteria, such as 
Bacillus, Brevibacillus, Clostridium, Paenibacillus, Staphylococcus, and E. coli.50, 51 The 
proteins of Cfr homologs have similar sizes ranging from 340 ~390 amino acids. Both 
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Cfr and Cfr(B) had 349 amino acids in length, and mutations have also been reported in 
Cfr in different bacteria.3, 5-7 However, Cfr(C) is significantly different from both Cfr and 
Cfr(B) (Figure. 3). It is 30 aa longer and only share ~55% identity with either of them. 
Interestingly, the N-terminal 352 aa of Cfr(C) is almost identical to the corresponding 
part of the ribosomal RNA large subunit methyltransferase N from P. difficile (Fig. S2). 
The 64 aa sequence at the C-terminus of the P. difficile methyltransferase was replaced 
by 27 aa in Cfr(C) in C. coli Tx40 (Fig. S2).  No homologs of the 27 aa sequence were 
found in the NCBI database. Therefore, whether the unique 27 aa in Cfr(C) protein forms 
a functional domain remains to be determined.  
 
Fig.3. Alignment of amino acid sequences of cfr, cfr(B) and cfr(C). The identical amino 
acids in the three proteins are shaded black. 
 
     At present, cfr(C) is mainly identified in C. coli isolates and the cfr(C)-positive 
isolates were from different feedlot cattle herds located in two different states. Based on 
the genotyping results from PFGE and MLST, the majority (33/34) of cfr(C)-containing 
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isolates were classified into a single clone, suggesting the possibility of clonal expansion 
of cfr(C)-positive C. coli in feedlot cattle in United States. This result also suggest the 
presence of a selection force (probably use of florfenicol) that has facilitated spread of 
this cfr(C)-positive clone. Although cfr(C) was not detected in the C. jejuni isolates 
examined in this study, we demonstrated the transfer of pTx40 from C. coli to C. jejuni 
under laboratory conditions. Thus, it is possible that cfr(C) may emerge in C. jejuni, 
which warrants further surveillance studies to monitor the spread of this multidrug 
resistance determinant in Campylobacter. 
     In summary, this study reports the identification and characterization of a novel 
plasmid-borne cfr variant, cfr(C) that confers resistance to multiple antibiotics in C. coli. 
To our best knowledge, this represents the first report of a cfr-like gene in a foodborne 
pathogen. The cfr(C) gene confers a PhLOPSA resistance phenotype similar to that of cfr 
and is carried on a conjugative plasmid, facilitating its dissemination in Campylobacter 
and to other bacterial species. The increasing prevalence of cfr(C) in Campylobacter by 
clonal expression and its potential transmission to humans via the foodborne route 
highlight its potential threat to public health. Thus enhanced efforts are needed to monitor 
and control the spread of cfr(C) in Campylobacter and other bacterial organisms. 
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CHAPTER 6. SUMMARY 
 
     Results from this project provide important information on the prevalence of C. jejuni 
SA and antibiotic resistance in Campylobacter in the U.S. cattle production systems.  A 
key finding of this project is the high prevalence of C. jejuni clone SA in both feedlot and 
dairy cattle. However, the prevalence in feedlot cattle varied significantly in different 
states and from farm to farm, and in dairy cattle, a declining trend in the prevalence was 
noticed from 2002 to 2014. These findings suggest that there might be factors that 
influence the prevalence of C. jejuni clone SA on cattle farms and underscore the need 
for future studies to identify the risk factors. Considering the significance of C. jejuni 
clone SA in ruminant health and food safety, reducing its prevalence and transmission on 
cattle farms will benefit both animal health and public health. 
     Fluoroquinolone (FQ) antibiotics are important for clinical treatment of human 
Campylobacter infections and are also frequently used for the prevention and control of 
respiratory infections in cattle. Another significant finding of this project is the high 
prevalence of FQ resistance in both C. jejuni and C. coli isolates derived from feedlot 
cattle. It’s especially alarming that the resistance rate in C. coli reached to 77%. Such a 
high-level prevalence of FQ resistance in ruminants was not reported in earlier studies 
conducted in the U.S. The reason for this rising trend in FQ resistance is uncertain, but it 
is likely due to the hyper-mutable nature of Campylobacter and the selection from use of 
FQ antimicrobials in the control of respiratory diseases in cattle production.  
Additionally, clonal expansion may have also contributed to the increasing prevalence of 
FQR Campylobacter. Development of FQ resistance is known to affect the fitness of 
Campylobacter in chickens, resulting in persistence of FQR Campylobacter even in the 
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absence of antibiotic selection pressure. Considering this possibility and the fact that FQs 
are continuously used for cattle production, it is possible that the prevalence of FQR 
Campylobacter will continue to rise. Thus, novel strategies are needed to curb the rising 
prevalence of FQ-resistant Campylobacter in cattle. For this reason, the dynamics of FQ 
resistance development and persistence in cattle should be evaluated in the context of 
antimicrobial dosages and the health status of the animals, which might contribute to the 
development of FQ-resistant Campylobacter. The fitness of FQ-resistant Campylobacter 
in cattle should also be examined in the absence of FQ antimicrobials to determine if the 
resistance can be mitigated by removing selection pressure.  
     Additionally, work in this project identified a novel plasmid-borne cfr variant, cfr(C), 
that confers resistance to multiple classes of antibiotics. To our best knowledge, this 
represents the first report of a cfr-like gene in a foodborne pathogen. The cfr(C) gene 
confers a PhLOPSA resistance phenotype similar to that of cfr. It’s emergence in bovine 
Campylobacter is unexpected and is likely driven by use of florfenicol in cattle 
production. Although florfenicol is not used for human clinical therapy and is not used 
for treating campylobacteriosis, its selection of cfr(C) in Campylobacter has other 
consequences as cfr(C) confers multidrug resistance and can be transmitted to other 
organisms via horizontal gene transfer. Furthermore, emergence of cfr(C) in foodborne 
organisms suggest the possibility of its transmission to humans via the foodborne routes. 
Thus, enhanced efforts are needed to monitor and control the spread of cfr(C) in 
Campylobacter and other foodborne bacterial organisms. 
In summary, studies in this project significantly enhanced our knowledge about 
Campylobacter epidemiology and antibiotic resistance in Cattle in the U.S. Findings from 
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this project not only closed key knowledge gaps, but also opened new directions for 
future research as discussed above. With continued and enhanced research efforts, it is 
possible that effective intervention strategies can be developed to mitigate 
Campylobacter prevalence and antibiotic resistance in cattle, which will ultimately 
benefit both cattle producers and consumers by improving ruminant health and enhancing 
food safety. 
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